Metabolites or derivatives of PROGESTERONE with hydroxyl group substitution at various sites.
Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY.
A metabolite of PROGESTERONE with a hydroxyl group at the 17-alpha position. It serves as an intermediate in the biosynthesis of HYDROCORTISONE and GONADAL STEROID HORMONES.
A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.
A 21-carbon steroid that is converted from PREGNENOLONE by STEROID 17-ALPHA-HYDROXYLASE. It is an intermediate in the delta-5 pathway of biosynthesis of GONADAL STEROID HORMONES and the adrenal CORTICOSTEROIDS.
An adrenal microsomal cytochrome P450 enzyme that catalyzes the 21-hydroxylation of steroids in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP21 gene, converts progesterones to precursors of adrenal steroid hormones (CORTICOSTERONE; HYDROCORTISONE). Defects in CYP21 cause congenital adrenal hyperplasia (ADRENAL HYPERPLASIA, CONGENITAL).
17,21-Dihydroxypregn-4-ene-3,20-dione. A 17-hydroxycorticosteroid with glucocorticoid and anti-inflammatory activities.
A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.
A metabolite of 17-ALPHA-HYDROXYPROGESTERONE, normally produced in small quantities by the GONADS and the ADRENAL GLANDS, found in URINE. An elevated urinary pregnanetriol is associated with CONGENITAL ADRENAL HYPERPLASIA with a deficiency of STEROID 21-HYDROXYLASE.
Saturated derivatives of the steroid pregnane. The 5-beta series includes PROGESTERONE and related hormones; the 5-alpha series includes forms generally excreted in the urine.
The condition of carrying TWINS simultaneously.
A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
A condition caused by the excessive secretion of ANDROGENS from the ADRENAL CORTEX; the OVARIES; or the TESTES. The clinical significance in males is negligible. In women, the common manifestations are HIRSUTISM and VIRILISM as seen in patients with POLYCYSTIC OVARY SYNDROME and ADRENOCORTICAL HYPERFUNCTION.
Steroids that contain a ketone group at position 17.
An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women.
Excess production of ADRENAL CORTEX HORMONES such as ALDOSTERONE; HYDROCORTISONE; DEHYDROEPIANDROSTERONE; and/or ANDROSTENEDIONE. Hyperadrenal syndromes include CUSHING SYNDROME; HYPERALDOSTERONISM; and VIRILISM.
A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.
A potent synthetic agonist of GONADOTROPIN-RELEASING HORMONE with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central PRECOCIOUS PUBERTY and ENDOMETRIOSIS.
An erectile structure homologous with the penis, situated beneath the anterior labial commissure, partially hidden between the anterior ends of the labia minora.
The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.
An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP).
The condition of carrying TRIPLETS simultaneously.
A microsomal cytochrome P450 enzyme that catalyzes the 17-alpha-hydroxylation of progesterone or pregnenolone and subsequent cleavage of the residual two carbons at C17 in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP17 gene, generates precursors for glucocorticoid, androgen, and estrogen synthesis. Defects in CYP17 gene cause congenital adrenal hyperplasia (ADRENAL HYPERPLASIA, CONGENITAL) and abnormal sexual differentiation.
A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.
A 21-carbon steroid, derived from CHOLESTEROL and found in steroid hormone-producing tissues. Pregnenolone is the precursor to GONADAL STEROID HORMONES and the adrenal CORTICOSTEROIDS.
A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.
The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.
Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power.
The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS.
A synthetic peptide that is identical to the 24-amino acid segment at the N-terminal of ADRENOCORTICOTROPIC HORMONE. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of CORTICOSTEROIDS in the ADRENAL CORTEX.
A pair of glands located at the cranial pole of each of the two KIDNEYS. Each adrenal gland is composed of two distinct endocrine tissues with separate embryonic origins, the ADRENAL CORTEX producing STEROIDS and the ADRENAL MEDULLA producing NEUROTRANSMITTERS.
Development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations below the mean age at onset of PUBERTY in the population. This early maturation of the hypothalamic-pituitary-gonadal axis results in sexual precocity, elevated serum levels of GONADOTROPINS and GONADAL STEROID HORMONES such as ESTRADIOL and TESTOSTERONE.
Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.
Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.
Exclusive legal rights or privileges applied to inventions, plants, etc.
A novel composition, device, or process, independently conceived de novo or derived from a pre-existing model.
Property, such as patents, trademarks, and copyright, that results from creative effort. The Patent and Copyright Clause (Art. 1, Sec. 8, cl. 8) of the United States Constitution provides for promoting the progress of science and useful arts by securing for limited times to authors and inventors, the exclusive right to their respective writings and discoveries. (From Black's Law Dictionary, 5th ed, p1014)
A condition in which the FORAMEN OVALE in the ATRIAL SEPTUM fails to close shortly after birth. This results in abnormal communications between the two upper chambers of the heart. An isolated patent ovale foramen without other structural heart defects is usually of no hemodynamic significance.
Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., GENETIC ENGINEERING) is a central focus; laboratory methods used include TRANSFECTION and CLONING technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction.
Time period from 1701 through 1800 of the common era.
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
The noninvasive measurement or determination of the partial pressure (tension) of oxygen and/or carbon dioxide locally in the capillaries of a tissue by the application to the skin of a special set of electrodes. These electrodes contain photoelectric sensors capable of picking up the specific wavelengths of radiation emitted by oxygenated versus reduced hemoglobin.
The use of specifically placed small electrodes to deliver electrical impulses across the SKIN to relieve PAIN. It is used less frequently to produce ANESTHESIA.
Revealing of information, by oral or written communication.
An island in the Greater Antilles in the West Indies. Its capital is San Juan. It is a self-governing commonwealth in union with the United States. It was discovered by Columbus in 1493 but no colonization was attempted until 1508. It belonged to Spain until ceded to the United States in 1898. It became a commonwealth with autonomy in internal affairs in 1952. Columbus named the island San Juan for St. John's Day, the Monday he arrived, and the bay Puerto Rico, rich harbor. The island became Puerto Rico officially in 1932. (From Webster's New Geographical Dictionary, 1988, p987 & Room, Brewer's Dictionary of Names, 1992, p436)
Hospitals located in metropolitan areas.
Persons living in the United States of Mexican (MEXICAN AMERICANS), Puerto Rican, Cuban, Central or South American, or other Spanish culture or origin. The concept does not include Brazilian Americans or Portuguese Americans.
Hospitals controlled by the city government.
Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.
A delicate membrane enveloping the brain and spinal cord. It lies between the PIA MATER and the DURA MATER. It is separated from the pia mater by the subarachnoid cavity which is filled with CEREBROSPINAL FLUID.
Condition of having pores or open spaces. This often refers to bones, bone implants, or bone cements, but can refer to the porous state of any solid substance.
Implantable devices which continuously monitor the electrical activity of the heart and automatically detect and terminate ventricular tachycardia (TACHYCARDIA, VENTRICULAR) and VENTRICULAR FIBRILLATION. They consist of an impulse generator, batteries, and electrodes.
Artificial substitutes for body parts, and materials inserted into tissue for functional, cosmetic, or therapeutic purposes. Prostheses can be functional, as in the case of artificial arms and legs, or cosmetic, as in the case of an artificial eye. Implants, all surgically inserted or grafted into the body, tend to be used therapeutically. IMPLANTS, EXPERIMENTAL is available for those used experimentally.
Machine readable patient or equipment identification device using radio frequency from 125 kHz to 5.8 Ghz.
Waves of oscillating electric and MAGNETIC FIELDS which move at right angles to each other and outward from the source.

The treatment of insulin resistance does not improve adrenal cytochrome P450c17alpha enzyme dysregulation in polycystic ovary syndrome. (1/235)

OBJECTIVE: To determine whether metformin. when given to non-diabetic women with polycystic ovary syndrome (PCOS), results in a reduction of insulin resistance and hyperinsulinemia while body weight is maintained. Also we aimed to see whether the reduction in insulin levels attenuates the activity of adrenal P450c17alpha enzyme in patients with PCOS. DESIGN: We investigated the 17-hydroxyprogesterone (17-OHP) and androstenedione responses to ACTH, insulin responses to an oral glucose tolerance test (OGTT) and glucose disposal rate in an insulin tolerance test before and after metformin therapy (500 mg, orally, twice daily, for 12 weeks). METHODS: The presence of hyperinsulinemia in 15 women with PCOS was demonstrated by an OGTT and results were compared with those of 10 healthy women. Insulin sensitivity was measured by the rate of endogenous glucose disposal after i.v. bolus injection of insulin. 17-OHP and androstenedione responses to ACTH were measured in all the women with PCOS and the normal women. RESULTS: Women with PCOS were hyperinsulinemic (102.0+/-13.0 (S.E.M.) VS 46.2+/-4.4 pmol/l) and hyperandrogenemic (free testosterone 15.3+/-1.7 vs 7.9+/-0.6 nmol/l; androstenedione 11.8+/-0.8 vs 8.2+/-0.6 nmol/l) and more hirsute (modified Ferriman-Gallwey score, 17.7+/-1.6 vs 3.0+/-0.3) than healthy women. In addition, women with PCOS had higher 17-OHP and androstenedione responses to ACTH when compared with healthy women. Metformin therapy resulted in some improvement in insulin sensitivity and reduced the basal and post-glucose load insulin levels. But 17-OHP and androstenedione responses to ACTH were unaltered in response to metformin. CONCLUSIONS: PCOS is characterized by hyperactivity of the adrenal P450c17alpha enzyme and insulin resistance. It seems that there is no direct relationship between insulin resistance and adrenal P450c17alpha enzyme dysregulation.  (+info)

Congenital adrenal hyperplasia: not really a zebra. (2/235)

Congenital adrenal hyperplasia was once considered a rare inherited disorder with severe manifestations. Mild congenital adrenal hyperplasia, however, is common, affecting one in 100 to 1,000 persons in the United States and frequently eluding diagnosis. Both classic and nonclassic forms of the disease are caused by deficiencies in the adrenal enzymes that are used to synthesize glucocorticoids. The net result is increased production from the adrenal gland of cortisol precursors and androgens. Even mild congenital adrenal hyperplasia can result in life-threatening sinus or pulmonary infections, orthostatic syncope, shortened stature and severe acne. Women with mild congenital adrenal hyperplasia often present with hirsutism, oligomenorrhea or infertility. Congenital adrenal hyperplasia is diagnosed by demonstration of excess cortisol precursors in the serum during an adrenal corticotropic hormone challenge. Diagnosis of congenital adrenal hyerplasia in fetuses that are at risk for congenital adrenal hyperplasia can be determined using human leukocyte antigen haplotype or by demonstration of excess cortisol precursors in amniotic fluid. Treatment includes carefully monitored hormone replacement therapy. Recognition of the problem and timely replacement therapy can reduce morbidity and enhance quality of life in patients that are affected by congenital adrenal hyperplasia.  (+info)

The effect of chronic treatment with GH on gonadal function in men with isolated GH deficiency. (3/235)

Eleven adult males, previously submitted to neurosurgery because of a pituitary lesion (three with craniopharyngioma, three with clinically non-functioning adenoma and five with macroprolactinoma) were treated with recombinant GH for 12 months after the diagnosis of GH deficiency was made. Circulating FSH, LH, prolactin, testosterone, 17 beta-estradiol (E2), dehyroepiandrosterone (DHEA-S), androstenedione. 17-OH-progesterone (17OHP), IFG-I, and steroid hormone-binding protein (SHBG) levels were assayed before and after CG test at study entry and 6 and 12 months after GH treatment. A significant increase in plasma IGF-I levels was obtained after 6 and 12 months of GH treatment. In addition, CG-stimulated, but not baseline, testosterone levels showed a significant increase after 6 and 12 months of GH treatment when compared with study entry (9.6 +/- 0.5 and 9.9 +/- 0.5 vs 7.9 +/- 0.5 ng/ml; P < 0.05). Baseline, but not CG-stimulated, serum 17OHP levels were significantly increased only after 12 months of GH treatment (1.7 +/- 0.1 vs 1.4 +/- 0.1 ng/ml; P < 0.05). No significant difference was found as far as both basal and CG-stimulated E2, androstenedione, DHEA-S and SHBG were concerned. With regards to the semen analysis, only seminal plasma volume was significantly increased after 12 months of GH treatment (2.9 +/- 0.3 vs 1.7 +/- 0.3 ml; P < 0.05). No significant change in sperm count, motility and abnormal forms was observed. These data show that GH treatment displays a clear-cut effect upon Leydig cell function and increases the production of seminal plasma volume in fertile adult males with isolated GH deficiency.  (+info)

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. (4/235)

BACKGROUND: Women with the polycystic ovary syndrome have insulin resistance and hyperinsulinemia, possibly because of a deficiency of a D-chiro-inositol-containing phosphoglycan that mediates the action of insulin. We hypothesized that the administration of D-chiro-inositol would replenish stores of the mediator and improve insulin sensitivity. METHODS: We measured steroids in serum and performed oral glucose-tolerance tests before and after the oral administration of 1200 mg of D-chiro-inositol or placebo once daily for six to eight weeks in 44 obese women with the polycystic ovary syndrome. The serum progesterone concentration was measured weekly to monitor for ovulation. RESULTS: In the 22 women given D-chiro-inositol, the mean (+/-SD) area under the plasma insulin curve after the oral administration of glucose decreased from 13,417+/-11,572 to 5158+/-6714 microU per milliliter per minute (81+/-69 to 31+/-40 nmol per liter per minute) (P=0.007; P=0.07 for the comparison of this change with the change in the placebo group); glucose tolerance did not change significantly. The serum free testosterone concentration in these 22 women decreased from 1.1+/-0.8 to 0.5+/-0.5 ng per deciliter (38+/-7 to 17+/-3 pmol per liter) (P=0.006 for the comparison with the change in the placebo group). The women's diastolic and systolic blood pressure decreased by 4 mm Hg (P<0.001 and P=0.05, respectively, for the comparisons with the changes in the placebo group), and their plasma triglyceride concentrations decreased from 184+/-88 to 110+/-61 mg per deciliter (2.1+/-0.2 to 1.2+/-0.1 mmol per liter) (P=0.002 for the comparison with the change in the placebo group). None of these variables changed appreciably in the placebo group. Nineteen of the 22 women who received D-chiro-inositol ovulated, as compared with 6 of the 22 women in the placebo group (P<0.001). CONCLUSIONS: D-Chiro-inositol increases the action of insulin in patients with the polycystic ovary syndrome, thereby improving ovulatory function and decreasing serum androgen concentrations, blood pressure, and plasma triglyceride concentrations.  (+info)

Adrenal 21-hydroxylase gene mutations in Slovenian hyperandrogenic women: evaluation of corticotrophin stimulation and HLA polymorphisms in screening for carrier status. (5/235)

OBJECTIVE: To study the incidence of 21-hydroxylase deficiency in Slovenian hyperandrogenic women, at the gene level. Previous endocrine studies indicated large differences in the incidence of 21-hydroxylase deficiency in hyperandrogenic women. The predictive values of the 17-hydroxyprogesterone (17-OHP) response to ACTH stimulation and of HLA typing in screening for carrier status were re-evaluated. DESIGN: Molecular analysis of CYP21 gene, ACTH stimulation and human leucocyte antigen (HLA) typing were performed in 83 consecutive Slovenian hyperandrogenic women. MEASUREMENTS: Cortisol and 17-OHP concentrations were measured at baseline and 60 min after ACTH stimulation. Basal adrenal androgen concentrations were also measured. RESULTS: None of 83 hyperandrogenic patients was affected with non-classical 21-hydroxylase deficiency, but 12 of 81 patients (14.8%) had high concentrations of 17-OHP after stimulation, indicative of carrier status. The increase in 17-OHP concentrations could be explained by a carrier status for CYP21 gene mutations in only three of 12 patients (25%), whereas seven of 69 patients (10. 1%) with normal concentrations of 17-OHP after stimulation were found to be carriers of CYP21 gene mutations, indicating low positive predictive values of ACTH stimulation as a screening test for carriers of 21-hydroxylase deficiency. In total, 11 carriers were identified among 83 patients: seven CYP21 gene deletions/conversions, two Gln(318)Stop and one Val(281)Leu mutation and one gene conversion extending from exon 4 to exon 7 were found. The association between Val(281)Leu mutation and HLA-B14 antigen was confirmed in this Slovenian population. CONCLUSIONS: Basal or ACTH-stimulated 17-OHP concentrations are not a good indicator of the carrier status for 21-hydroxylase deficiency among Slovenian hyperandrogenic patients. Reliable screening for carriers of 21-hydroxylase deficiency is possible only by molecular analysis of the CYP21 gene.  (+info)

Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. (6/235)

The aim of this study was to examine the echocardiographic profiles of patients with polycystic ovarian syndrome (PCOS). Serum concentrations of follicle stimulating hormone, luteinizing hormone, androstenedione, free testosterone, prolactin, DHEA-SO(4) and 17-OH-progesterone, lipid profile (high and low density lipoproteins, triglyceride and total cholesterol) and basal and total insulin after a glucose tolerance test were measured in 35 patients with PCOS and 35 healthy controls matched for body mass index. Doppler, two dimensional M mode echocardiography was performed for the following indices: isovolumetric relaxation time (IVRT), E wave duration time (EVT), A wave duration time (AVT), E wave deceleration time (DT), peak early diastolic flow velocity (PEV), peak late diastolic flow velocity (PAV), E wave velocity time integral (FVI-E), A wave velocity time integral (FVI-A), atrial filling fraction (AFF), ejection fraction (EF), pre-ejection time (PEP), ejection time (ET) and aortic flow velocity time integral (FVI). Androstenedione, free testosterone, low density lipoproteins and cholesterol concentrations were significantly higher in patients with PCOS. There was no difference in basal and total insulin concentrations. IVRT, AVT, FVI-A, AFF, and PEP were higher in patients with PCOS, while PEV, FVI-E, EF, ET, EVT and EVT/AVT were higher in the control group. There was a positive correlation between basal insulin values and IVRT, and between total insulin values and EF. These changes are consistent with a non-restrictive type of diastolic dysfunction and left ventricular stiffness. PCOS may lead to diastolic dysfunction via hyperinsulinaemia and male type dyslipidaemia.  (+info)

Aortic plaque size and endometrial response in cholesterol-fed rabbits treated with estrogen plus continuous or sequential progestin. (7/235)

ERT is associated with a reduced incidence of coronary risk and cardiac events in postmenopausal women, but increases the risk of endometrial hyperplasia and carcinoma. Combined estrogen and progestin therapy protects the endometrium; however, its effects on heart disease risk factors are not completely known. In our study, 56 ovariectomized New Zealand White rabbits in 7 groups received a 0.5% cholesterol diet for 12 weeks. Controls were not treated with hormones. All other animals received (per kilogram body weight per week) intramuscular injections of either 0.3 mg estrogen (estradiol valerate) alone, 8.3 mg progestin (hydroxyprogesterone caproate) alone, estrogen and progestin continuously in 3 different dosages (0.3 and 8.3 mg; 1 and 8.3 mg; or 1 and 2.8 mg; estrogen and progestin, respectively), or 1 mg estrogen with 25 mg progestin sequentially in 2-week cycles. Eight non-ovariectomized animals served as further controls for endometrial analysis. Morphometric analysis of plaque size in the aortic arch showed that estrogen monotherapy, and the 3 combined therapies with 1 mg estrogen, significantly reduced intimal thickening (P<0.05). The application of progestin alone had no effect on plaque size. The endometrium was enlarged by 3-fold after estrogen treatment, and was decreased by half after progestin treatment, compared with control uteri (P<0.05). In all groups with combined hormone regimens, endometrial size was not significantly different from control uteri. However, these uteri showed more inflammatory reactions, especially when higher doses of hormones were given. In this animal model, doses of progestin that are able to successfully reduce the proliferative effect of estrogen on endometrium do not diminish the desirable antiatherosclerotic properties of estrogen.  (+info)

Longitudinal measurements of 17alpha-hydroxyprogesterone in premature infants during the first three months of life. (8/235)

AIMS: To determine normal concentrations of 17alpha-hydroxyprogesterone (17OHP) for premature infants. METHODS: 17OHP was measured in 66 consecutive premature infants once a week during the first month, and once every two weeks thereafter, until the age of 3 months. The 17OHP values in 100 full term healthy neonates on the third day of life served as controls. Blood was sampled on filter paper using a neonatal radioimmunoassay kit. Findings were correlated with gestational age, birthweight, mode of delivery, Apgar scores, presence of respiratory distress syndrome and intake of maternal steroids. RESULTS: Mean 17OHP was raised at 7 days of age (138.9, 46.3, 53.3, 29.9 nmol/l, respectively, for infants whose gestational age was under 29 weeks, 29 to 30 weeks, 31 to 32 weeks, and 33 weeks and above). It fell sharply in the first two weeks after which it gradually decreased further, reaching 32.7, 23.6, 16.9, and 13.0 nmol/l, respectively, by the age of 90 days. The mean (SEM) 17OHP concentration in full term infants on day 3 of life was 17.8 (8.9) nmol/l. These values were independent of the presence and severity of respiratory distress syndrome and of prenatal maternal steroids. CONCLUSIONS: The increased 17OHP concentrations found at birth fell to those found in term infants during the first three months of life in infants over 31 weeks of gestation. Postconceptional age is the most important factor determining 17OHP concentration.  (+info)

Definition of 17-alpha-hydroxyprogesterone in the Definitions.net dictionary. Meaning of 17-alpha-hydroxyprogesterone. What does 17-alpha-hydroxyprogesterone mean? Information and translations of 17-alpha-hydroxyprogesterone in the most comprehensive dictionary definitions resource on the web.
hydroxyprogesterone - MedHelps hydroxyprogesterone Center for Information, Symptoms, Resources, Treatments and Tools for hydroxyprogesterone. Find hydroxyprogesterone information, treatments for hydroxyprogesterone and hydroxyprogesterone symptoms.
Hydroxyprogesterone is a form of progestin, a manmade form of a female hormone called progesterone. Hydroxyprogesterone is used to lower the risk of premature birth in a woman who has already had one premature baby. This medication will not stop premature labor that has already begun. Hydroxyprogesterone is not for...
Describes how the 17-hydroxyprogesterone (17-OHP) test is used, when a 17-OHP test is ordered, and what the results of a 17-hydroxyprogesterone test might mean
The reference range of urinary 17-hydroxyprogesterone (17-OHPG) in children is as follows: Age 3 days to 1 year: Up to 50 ng/24 hours Age 1-8 years: Up to 300 ng/24 hours The following is the reference of urinary 17-OHPG in adults: Males: Up to 2 µg/24 hours Females: Up to 4.5 µg/24 hours .
21-Hydroxyprogesterone,ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories client,medicine,medical supply,medical supplies,medical product
Manufacturer of Gynae Pharma Franchise - Hydroxyprogesterone Injection ( Myterm -H 500 ) Inj, Gynae PCD Pharma Franchise offered by Corazon (A Division Of Arlak Biotech Private Limited), Zirakpur, Punjab.
Gonadectomized male rats of Wistar strain were administered 3H-progesterone. Various brain tissues and anterior pituitary were analyzed for retention of radioactivity, using a liquid scintillation technique. Radioactivity, in all tissues, was highe
In addition to the 17-OH-Progesterone (OHP), we are now able to offer an expanded adrenal steroid hormone profile which includes Cortisol, OHP, Progesterone, E2, Testosterone and Androstenedione. This gives a complete picture of the adrenal status.. A standard ACTH stimulation test (see p22) should be performed. At least 2 mLs of serum or plasma is required to carry out all the analysis.. ...
This medication is used in women who are pregnant with a single baby, and who have delivered a baby too early (preterm) in the past.
Progesterone + [Reduced NADPH---hemoprotein reductase] + Oxygen ,=> 17alpha-Hydroxyprogesterone + [Oxidized NADPH---hemoprotein reductase] + ...
EIAab can provide you General 17-Hydroxyprogesterone ELISA Kit(General 17OHP ELISA Kit) with more favourable price and high quality.
Background: 42 y/o No aas or pro hormone history 61 200lbs Lift 4 times/week 2 push 2 pull Push: 6 sets 8 ohp 6 sets 8 dips (forward lean) 6 sets 8
11β-Hydroxyprogesterone (11β-OHP), also known as 21-deoxycorticosterone, as well as 11β-hydroxypregn-4-ene-3,20-dione, is a naturally occurring, endogenous steroid and derivative of progesterone. It is a potent mineralocorticoid. Increased levels of 11β-OHP occur in 21-hydroxylase deficiency. Along with its epimer 11α-hydroxyprogesterone (11α-OHP), 11β-OHP has been identified as a very potent competitive inhibitor of both isoforms (1 and 2) of 11β-hydroxysteroid dehydrogenase (11β-HSD). 21-Deoxycortisol (11β,17α-dihydroxyprogesterone) 11-Deoxycorticosterone (21-hydroxyprogesterone) Corticosterone (11β,21-dihydroxyprogesterone) Cortisol (11β,17α,21-trihydroxyprogesterone) 11-Deoxycortisol (17α,21-dihydroxyprogesterone) 9α-Bromo-11-ketoprogesterone Human Metabolome Database: Showing metabocard for 11b-Hydroxyprogesterone (HMDB04031). hmdb.ca. Retrieved 2016-12-16. Souness GW, Latif SA, Laurenzo JL, Morris DJ (1995). 11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of ...
11α-Hydroxyprogesterone (11α-OHP), or 11α-hydroxypregn-4-ene-3,20-dione is an endogenous steroid and metabolite of progesterone. It is a weak antiandrogen, and is devoid of androgenic, estrogenic, and progestogenic activity. It was investigated as a topical antiandrogen for the treatment of androgen-dependent skin conditions in the early 1950s, and was found to produce some benefit. In 1995, 11α-OHP, along with its epimer 11β-hydroxyprogesterone, was identified as a very potent competitive inhibitor of both isoforms (1 and 2) of 11β-hydroxysteroid dehydrogenase (11β-HSD). It is notably not metabolized by 11β-HSD2. 11α-OHP is a more potent inhibitor of 11β-HSD than enoxolone (glycyrrhetinic acid) or carbenoxolone in vitro (IC50 = 0.9 nM; IC50 = 5 nM in transfected cells). The compound has been found to be highly active in conferring mineralocorticoid sodium-retaining activity of corticosterone in vivo in rat bioassays and in increasing blood pressure, effects that it mediates by ...
The 17-hydroxyprogesterone test is mainly used to check for the most common form of the genetic disorder congenital adrenal hyperplasia (CAH) in infants and children.
Cookies are important for the proper functioning of a website. In order to improve your experience, we use cookies to keep the login information and provide a secure connection, collect the statistics to optimize the functionality of the website and adapt the content to your interests. Click on Accept and Continue to accept cookies and access to the website or you can refer to our Privacy Policy.. ...
Disease, Amyloid, Biomarkers, Growth, Role, Cerebrospinal Fluid, Threonine, Fibroblast Growth Factor, Hormone, Methods, Measure, 17-hydroxyprogesterone, Congenital Adrenal Hyperplasia, Development And Growth, Hormones, Hyperplasia, Meningiomas, Progesterone, Progesterone Receptors, Quality Control
A microsomal cytochrome P-450 (heme-thiolate) protein that catalyses two independent reactions at the same active site - the 17-hydroxylation of pregnenolone and progeste
Describes how the androstenedione test is used, when an androstenedione test is ordered, and what the results of an androstenedione test might mean
We 41,275 mm x 45,244 mm x 38,1 mm Provide Extensive BEARING INDUSTRIA CUSCINETTI S.P.A. 41,275 mm x 45,244 mm x 38,1 mm skf PCZ 2624 M Plain bearings,Bushings Selection And Competitive Wholesale Pricing.
מאמרים (כתבות) עם התגית androstenedione: 57(1) Full article PDF, 59(1) Full article PDF, Contents of 57(1), 2005, Contents of 59(1), 2007, ועוד...
Biochemistry;Hydroxyketosteroids;Steroids;Steroid and Hormone;Hormone Drugs, Hydroxyprogesterone caproate - Drug, 17 hydroxyprogesterone caproate, 17 hydroxyprogesterone, hydroxyprogesterone caproate injection, alpha hydroxyprogesterone caproate, 17 alpha hydroxyprogesterone, massachusetts veterinarian, hydroxyprogesterone, massachusetts veterinarians, hydroxy progesterone,
We offer to book Congenital Adrenal Hyperplasia (CAH) Test online for Newborn Screening. View Congenital Adrenal Hyperplasia (CAH) Test cost, pre test information and report availability on trutestlab.com. Home collection of blood sample is also available at our centers.
3. Androgens, which are responsible for the development of secondary sexual characteristics (adrenarche) in both males and females.. All three of these adrenal hormones are necessary for normal body functioning in both males and females. In patients with Congenital Adrenal Hyperplasia, the adrenal glands typically produce too little cortisol and aldosterone, while producing too much of the androgen hormones. Excess levels of androgens can cause atypical genitalia, growth abnormalities, early puberty, and problems with fertility. All infants born in the United States are screened for Congenital Adrenal Hyperplasia shortly after birth. If your child is diagnosed with Congenital Adrenal Hyperplasia, additional tests including blood tests and imaging tests, such as X-rays or ultrasounds, are often done. Ultimately, genetic testing is used to confirm the diagnosis.. CAH is a condition that requires long-term follow-up and monitoring. The treatment involves life-long cortisol with or without ...
Get information, facts, and pictures about Congenital adrenal hyperplasia at Encyclopedia.com. Make research projects and school reports about Congenital adrenal hyperplasia easy with credible articles from our FREE, online encyclopedia and dictionary.
Introduction: 21-Hydroxylase deficiency is the most frequent form of congenital adrenal hyperplasia (CAH) which is a common autosomal recessive disorder characterized by impaired adrenocortical and adrenomedullary function, and adrenal hyperandrogenism. Chronic glucocorticoid therapy and excess androgen exposure in patients with CAH may predispose them to developing a metabolic syndrome in adulthood.Our objective is to evaluate the metabolic syndrome in adulthood in a Tunisian cohort.. Subjects and Methods: We underwent a prospective study of 26 patients over 16 years of old with CAH.. Results: The cases included 26 patients (M: 11, F: 15) with CAH due to 21-hydroxylase deficiency with a mean age of 27.4 years (16.5-48 years). Eighteen patients had the classical CAH form and the remaining 8 patients had the non-classical form. The mean body mass index was 26,9 ± 4,27 kg/m2 (20,3-34,8 kg/m2). The most commonly used drug was hydrocortisone which was used by 21 cases. Five cases had been managed ...
Defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol accounts for more than 90 percent of cases of congenital adrenal hyperplasia (CAH). This conversion is mediated by 21-hydroxylase, the enzyme encoded by theCYP21A2gene.Patients with c
TY - JOUR. T1 - Stigma in medical settings as reported retrospectively by women with Congenital Adrenal Hyperplasia (CAH) for their childhood and adolescence. AU - Meyer-Bahlburg, Heino F.L.. AU - Khuri, Jananne. AU - Reyes-Portillo, Jazmin. AU - New, Maria I.. PY - 2017/1/1. Y1 - 2017/1/1. N2 - Objectives To perform a qualitative study of stigma experienced in medical settings by children and adolescents with congenital genital ambiguity (CGA). Methods 62 women with classical congenital adrenal hyperplasia (CAH) of variable severity took part in a qualitative retrospective interview that focused on the impact of CAH and its medical treatment, with an emphasis on childhood and adolescence. Categorization of stigmatization was based on deductive content analysis of the interview transcripts. Results Many women recalled experiencing the genital examinations in childhood and adolescence as adverse, stigmatizing events, leading to avoidance reactions and self-perception as abnormal, particularly ...
There is no clear consensus among state newborn screening programs on whether routine second screening of newborns identifies clinically relevant cases of congenital adrenal hyperplasia. This retrospective study evaluated laboratory practices, along with biochemical and medical characteristics of congenital adrenal hyperplasia (CAH) cases (1) detected on the first newborn screen in one-screen compared to two-screen states, and (2) detected on the first versus the second screen in the two-screen states, to determine the effectiveness of a second screen. A total of 374 confirmed cases of CAH from 2 one-screen states and 5 two-screen states were included in this study. Demographic data and diagnostic information on each reported case were collected and analyzed. Additionally, laboratory data, including screening methodologies and algorithms, were evaluated. The one-screen states reported 99 cases of CAH out of 1,740,586 (1 in 17,500) newborns screened: 88 (89%) identified on the first screen and 5 ...
Congenital Adrenal Hyperplasia in males (CAH), symptoms, causes and treatment of Congenital Adrenal Hyperplasia, parents should always get themselves treated in all manner of conditions before going ahead to bear children.
To determine the glucocorticoid receptor (GC-R) status in congenital adrenal hyperplasia (CAH) we examined 11 patients (5 female, 6 male) with 21-hydroxylase deficiency and 3 patients (2 female, 1 male) with 11 beta -hydroxylase deficiency, The mean age at investigation was 8.9+/-3.5 yr, Age of diagnosis was 4.4+/-3.2 yr and all patients were being treated with hydrocortisone, The control group included 10 (5 female, 5 male) age-matched healthy children. Blood samples were drawn at 0800 a.m. after an overnight fast in all subjects and after 5 days off treatment in patients with CAH. Serum cortisol tin all children), and serum 17-hydroxyprogesterone and androstenedione tin the patient group) were measured by radioimmunoassay, Mononuclear leukocytes were isolated from peripheral blood and the binding of [H-3]dexamethasone to GC-R was examined. GC-R number and the dissociation constant (Kd), which is inversely proportional to its binding affinity, were determined, Mean GC-R numbers were 5814+/-1574 ...
CAH21 : Preferred screening test for congenital adrenal hyperplasia (CAH) that is caused by 21-hydroxylase deficiency   Part of a battery of tests to evaluate females with hirsutism or infertility, which can result from adult-onset CAH
Congenital adrenal hyperplasia (CAH) is a common genetic endocrine disorder, with 21-hydroxylase enzyme deficiency accounting for 95% of the cases. 21-hydroxylase deficiency presents with a spectrum of clinical manifestations ranging from salt-wasting and virilization of female neonates (classic CAH) to symptomatic (precocious puberty, short stature, acne) or asymptomatic hyperandrogenemia (non-classic CAH). Classic CAH is characterized by impaired cortisol and mineralocorticoid biosynthesis, which triggers adrenocorticotropic hormone (ACTH) hyper-secretion and accumulation of adrenal androgens. Glucocorticoid treatment of patients with classic CAH focuses on cortisol replacement and prevention of the ACTH-driven androgen excess. Current conventional glucocorticoid treatment regimens (short or long-acting agents dosed once, twice or thrice daily) have failed to simulate physiological cortisol secretion and suppress adrenal androgen overproduction, without supraphysiologic replacement. Short-term ...
Background: Newborn screening for congenital adrenal hyperplasia (CAH) is based on the determination of 17-hydroxyprogesterone (17OHP) on blood and its need is confirmed by the most recent guidelines on the subject. In Italy this screening is not mandatory, and its application is on a regional basis. Among its disadvantages, it is well known the high frequency of false-positives, in particular in premature babies and those born small for gestational age. However, there are a number of subjects who are false-negatives (FN), with the risk of late diagnosis and development of complications.. Case report: A 4-year-old boy presented with pubic hair, body odor and acne noted one year earlier. At clinical examination, height was 125.1 cm (+3.85 SDS, target height +0,70 SDS), weight 25,1 kg (+2 SDS) and he had mild acne in his face. He was Tanner stage 2 (G2PH3, testicular volume 4 ml bilaterally). Bone age was 12-13 years. In his previous medical history, he was recalled for CAH screening performed at ...
This thread is over a year old but I thought I would check in on you. How are you now? Here is something that may help with what your dealing with. Im 43 years old and a female in 1993 I was diagnosed with Congenital Adrenal Hyperplasia 21 OH deficiency I had a stress dose of cortisol for adrenal crisis and was sent home with no other instructions. Being a young mother and ignorant of this condition I thought it was a one time event and tried to move on with my life. Needless to say for twenty some odd years I had no idea I was in trouble. I had an ACTH stimulation test that showed a morning cortisol of 16 the 17 hydroxyprogesterone level was 10,900 at thirty minutes. I asked for an adrenal washout CT scan and it showed a .09 x 1.3 cm growth on my left adrenal gland. These can produce excess cortisol but is you are CAH 21 OH deficient you cant use it and full physiologic replacement should be given. I recommend Dr Maria New at Mount Sanai hospital in New York she is an expert in ...
Congenital adrenal hyperplasia (CAH) is caused by the genetic impairment of one of the five enzymes required for the biosynthesis of cortisol from cholesterol. In 95% of cases 21-hydroxylase deficiency (21-OHD) is responsible for the disease (1). Classic 21-OHD has an incidence varying from 1:11 800 to 1:21 800, depending on the population background. The pathophysiology, clinical picture, genetics, and the unique aspects of management from the point of view of the paediatric endocrinologist are addressed, and the problems encountered from birth to puberty are described. The child specific issues of rare forms of CAH are summarized thereafter. The reader is referred to Chapter 5.11 for a comprehensive overview of 21-OHD and for more details on all other forms of CAH.. ...
Congenital adrenal hyperplasia (CAH) is a problem that affects how the adrenal glands work. The adrenal glands need an enzyme to make certain hormones. Children with CAH are missing or have low levels of this enzyme.. The hormones produced by the adrenal glands affect nearly every organ in the body. They help the body cope with stress, hold salt and water, and maintain blood pressure. They also affect sexual development.. CAH is a problem that is passed through genes. Most of the time its found during routine newborn blood tests.. When a child has CAH, he or she will need to take medicine each day to replace the missing hormones.. You may have just learned that your baby has CAH. You will get more information and support from the hospital staff. ...
Congenital adrenal hyperplasia (CAH) is a genetic disorder caused by defective steroidogenesis that results in glucocorticoid deficiency; the most common underlying mutation is in the gene that encodes 21-hydroxylase. Life-saving glucocorticoid treatment was introduced in the 1950s, and the number of adult patients is now growing; however, no consensus has been reached on the management of CAH beyond childhood. Adult patients are prescribed a variety of glucocorticoids, including hydrocortisone, prednisone, prednisolone, dexamethasone and combinations of these drugs taken in either a circadian or reverse circadian regimen. Despite these personalized treatments, biochemical control of CAH is only achieved in approximately one-third of patients. Some patients have a poor health status, with an increased incidence of obesity and osteoporosis, and impaired fertility and quality of life. The majority of poor health outcomes seem to relate to inadequate treatment rather than the genotype of the patient.
Molecular Identification of Intron 2 Splice Mutation and 8bp Deletion in CYP21 Gene for Congenital Adrenal Hyperplasia (CAH) Patients in Kashmir (North India) Abstract.
Congenital Adrenal Hyperplasia causes a cortisol deficiency in infants, children and adolescents and can be treated by Pediatric Endocrine Associates
Female patients with congenital adrenal hyperplasia have been frequently studied in order to determine the impact of prenatal androgen exposure on various aspects of psychological, psychosocial and...
Doctors at Hassenfeld Childrens Hospital at NYU Langone diagnose classic and nonclassic types of congenital adrenal hyperplasia in children. Read more.
TY - JOUR. T1 - Congenital adrenal hyperplasia. AU - White, P. C.. AU - New, M. I.. AU - Dupont, B.. PY - 1987. Y1 - 1987. UR - http://www.scopus.com/inward/record.url?scp=0023226909&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0023226909&partnerID=8YFLogxK. M3 - Article. C2 - 3295546. AN - SCOPUS:0023226909. VL - 316. SP - 1580. EP - 1586. JO - New England Journal of Medicine. JF - New England Journal of Medicine. SN - 0028-4793. IS - 25. ER - ...
An education and support network for people and families with Congenital Adrenal Hyperplasia. Includes important medical links, FAQ, Message Board and Archives.
An education and support network for people and families with Congenital Adrenal Hyperplasia. Includes important medical links, FAQ, Message Board and Archives.
17a-Hydroxypogesterone (17aOHP) is a steroid intermediate in the biosynthesis of glucocorticoids. It is produced in the testes, ovary and adrenal. The main clinical use of this assay is in the diagnosis and monitoring of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.. ...
Another name for Adrenal Hyperplasia is Congenital Adrenal Hyperplasia. Treatment for congenital adrenal hyperplasia usually includes hormone therapy ...
There are two types of CAH. The first called Classical CAH which is usually detected through prenatal testing or diagnosed in early childhood. When the pituitary gland senses there is insufficient cortisol in the bloodstream, it releases a hormone called ACTH (adrenocorticotropic hormone). This, in turn, stimulates the adrenals to produce more cortisol. The enzyme 21-hydroxylase is needed to convert a precursor molecule called 17-hydroxyprogesterone (17-OHP) into cortisol, but those with CAH lack sufficient amounts of 21-hydroxylase causing the pituitary gland to pump out more ACTH when it senses the need for cortisol. The adrenals convert an overabundance of 17-OHP into masculine steroid hormones called androgens. As stated before, adrenal glands are responsible for creating cortisol, in order to maintain adequate energy supply and blood sugar levels, and deal with physical and emotional stress. Lack of adequate cortisol also prevents the body from properly metabolizing sugar and responding to ...
7-hydroxyprogesterone: formed by the hydroxylation of progesterone by extracts of Phycomyces blakesleeanus; RN given refers to (alpha)-isomer; RN for cpd without isomeric designation not avail 4/91
11β-hydroxylase deficiency (11β-OHD), an autosomal recessive inherited disorder, accounts for 5-8% of congenital adrenal hyperplasia. In Greece, no cases of 11β-OHD have been described so far. The patient presented at the age of 13 months with mild virilization of external genitalia and pubic hair development since the age of 3 months. Hormonal profile showed elevated 11-deoxycortisol, adrenal androgens and ACTH levels. ACTH stimulation test was compatible with 11β-OHD. DNA of the proband and her parents was isolated and genotyped for CYP11B1 gene coding cytochrome P450c11. The girl was found to be compound heterozygous for two CYP11B1 novel mutations, p.Ala386Glu (exon 7), inherited from the father and p.Leu471Argin (exon 9) from the mother. Hydrocortisone supplementation therapy was initiated. Four years after presentation she remains normotensive, her growth pattern is normal and the bone age remains advanced despite adequate suppression of adrenal androgens. ...
Congenital adrenal hyperplasia (CAH) is a genetic disorder arising from defective steroidogenesis resulting in glucocorticoid deficiency; the commonest mutation is in the gene encoding 21-hydroxylase. Lifesaving glucocorticoid treatment was introduced in the 1950s and there is now an enlarging cohort of adult patients; however, there is no consensus on management. To address this issue, the Congenital adrenal Hyperplasia Adult Study Executive (CaHASE) was formed in 2003 to study the health status of CAH patients in adulthood. Seventeen specialist Endocrinology centres around the United Kingdom recruited a cohort of 203 adult patients and gathered information on medical treatment, fertility, genetic analysis and quality of life (QoL). The CaHASE study found that adult patients are prescribed a variety of glucocorticoids including hydrocortisone, prednisone, prednisolone, dexamethasone, and combinations taken in either a circadian or reverse circadian regimen. Despite this variety in personalized ...
With careful treatment it should be possible for children with CAH to grow at a rate sufficient to achieve an adult height within the normal range. However, even with the very best treatment, it is not always possible to achieve perfect growth in CAH, and some individuals may end up shorter adults than they would otherwise have been. Also, the dose of hydrocortisone required to control the CAH may make it difficult for some children to keep their weight down, and this can be a particular problem for girls at adolescence. It may be helpful to have the input of a dietician - you should discuss this with your specialist. ...
With careful treatment it should be possible for children with CAH to grow at a rate sufficient to achieve an adult height within the normal range. However, even with the very best treatment, it is not always possible to achieve perfect growth in CAH, and some individuals may end up shorter adults than they would otherwise have been. Also, the dose of hydrocortisone required to control the CAH may make it difficult for some children to keep their weight down, and this can be a particular problem for girls at adolescence. It may be helpful to have the input of a dietician - you should discuss this with your specialist. ...
OVERVIEW: What every practitioner needs to know Are you sure your patient has congenital adrenal hyperplasia? What are the typical findings for this disease? Congenital adrenal hyperplasia (CAH) describes a group of autosomal recessive disorders resulting from a deficiency in one of the enzymes involved in adrenal steroid synthesis. Impaired cortisol synthesis leads to chronic…. ...
An inherited condition that affects the adrenal glands. These glands are located on top of the kidneys and produce three types of hormones called cortisol, aldosterone and androgens. Females with classical CAH are born with masculine appearing external genitals but with female internal sex organs. Males with classical CAH appear normal at birth. Males and females with classical CAH are likely to have trouble retaining salt, a condition that can be life threatening.
Adrenal gland- ito ay isang organ na matatagpuan sa ibabaw ng kidneys. Ito ang gumaganap upang magbigay ng hormones na kinakailangan ng katawan para sa normal function. Ang mga hormones na lumalabas sa adrenal glands ay cortisol , aldosterone at androgen. ...
Cardiology news, research and treatment articles offering cardiology healthcare professionals cardiology information and resources to keep them informed.
Black Swan Analysis Limited, Moorbridge Court, 29-41 Moorbridge Road, Maidenhead, Berkshire, SL6 8LT, United Kingdom - Tel: 01628 621 790 ...
Dr. Alan Jacobs has helped many patients with anxiety disorders caused by adrenal issues, including the woman in this case study.
Поздние осложнения классической формы врожденной дисфункции коры надпочечников и ее неадекватного лечения у мужчин (клинический случай с обзором литературы)
You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our cookies policy. ...
We offer clinical cancer updates, treatment guidance, and research news to the oncology nursing community. Visit us often for drug therapy testing results, patient care information and more. Download our FREE app today.
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the users own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer ...
Children. Preterm infants. Preterm infants may exceed 630 ng/dL, however, it is uncommon to see levels reach 1,000 ng/dL.. Term infants. 0-28 days: ,630 ng/dL. Levels fall from newborn (,630 ng/dL) to prepubertal gradually within 6 months.. Prepubertal males: ,110 ng/dL. Prepubertal females: ,100 ng/dL Adults. Males: ,220 ng/dL. Females. Follicular: ,80 ng/dL. Luteal: ,285 ng/dL. Postmenopausal: ,51 ng/dL. Note: For pregnancy reference ranges, see: Soldin OP, Guo T, Weiderpass E, et al: Steroid hormone levels in pregnancy and 1 year postpartum using isotope dilution tandem mass spectrometry. Fertil Steril 2005 Sept;84(3):701-710. ...
[Determination of serum steroids in monitoring therapy of congenital adrenal hyperplasia].: Each of serum 17-OHP or/and Δ4-A concentration was of significance i
Chronocort vs. Cortef Cortisol Concentrations (AUC Over 24 Hours - Time Points 0,.5,1,1.5,2,3,4,5,6,7,8,10,10.5,11, 11.5,12,13,15,17,17.5,18,18.5,19,20,22,24 Post Dose ...
Whereas hydroxyprogesterone acetate (the 6α-demethylated analogue of medroxyprogesterone acetate) is around twice as potent as ... 3-hydroxyprogesterone. * Prodox, Upjohn Co., Kalamazoo, Michigan [...] It was found that 17-a-hydroxyprogesterone acetate has a ... doi:10.1210/jcem-17-10-1237. PMID 13475464. It is the purpose of this paper to introduce and describe a new steroid for oral ... Dimethisterone, also known as 6α,21-dimethylethisterone or as 6α,21-dimethyl-17α-ethynyltestosterone, as well as 17α-ethynyl-6α ...
Note that 3,17-diacetoxy-6-methylpregna-4,6-dien-20-one (1b), a structural analog of compound 1a, is certified in Russia under ... It is very close to megestrol acetate (6-dehydro-6-methyl-17α-acetoxyprogesterone) in structure, except that there is a ... A closely related medication is cymegesolate (also known as megestrol 3β-cypionate 17α-acetate), which, in contrast, has not ... Nikitina GV, Savchenko ON, Stepanov MG (1987). "[Hormonal properties of new 17 alpha-hydroxyprogesterone derivatives]". ...
2alpha-Methylen-delta-17alpha-hydroxy-progesteronen". "6-chloro-1, 2alpha-methylene-delta6-17alpha-hydroxyprogesterone ... hydroxyprogesterone caproate, medroxyprogesterone acetate, and megestrol acetate. Chemical syntheses of CPA have been published ... Deutsch M (17 June 2016), Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People (PDF ... 17 (4): 405-25. doi:10.1016/S0149-7634(05)80117-4. PMID 8309650. S2CID 28557481. Thibaut F, Kuhn JM, Colonna L (August 1991). " ...
... such as hydroxyprogesterone caproate, medroxyprogesterone acetate, and cyproterone acetate, are highly active themselves (in ... and hydroxyprogesterone caproate, the 19-norprogesterone derivative nomegestrol acetate, and the 19-nortestosterone derivatives ... hydroxyprogesterone, medroxyprogesterone, and cyproterone, respectively). On the other hand, esters of 19-nortestosterone ... One promising ester, [17α-hydroxyprogesterone acetate], marketed as Prodox, was found. It was more active by mouth than other ...
An active metabolite of progesterone, 11-deoxycorticosterone (21-hydroxyprogesterone), is a precursor of aldosterone and has ... 17 (6): 754-9. doi:10.1210/jcem-17-6-754. PMID 13428841. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (25 August 2011 ... 17α-Hydroxyprogesterone caproate is a depot progestogen which is entirely free of side actions. The dose required to induce ... However, a higher 17-OHP level was observable at the completion of OMP administration (week 2). Sitruk-Ware R (2002). " ...
ISBN 978-1-259-64116-9. In addition to progesterone, 20α- and 20β-hydroxyprogesterone (20α- and 20β-hydroxy-4-pregnene-3-one) ... include 16α-hydroxyprogesterone (16α-OHP), 17α-hydroxyprogesterone (17α-OHP) (very weak), 20α-dihydroprogesterone (20α-DHP), 20 ... "16α-hydroxyprogesterone: origin, biosynthesis and receptor interaction". Mol. Cell. Endocrinol. 336 (1-2): 92-101. doi:10.1016/ ... These progestogens, along with another steroid, 17α-hydroxypregnenolone, are the precursors of all other endogenous steroids, ...
van Rooyen D, Gent R, Barnard L, Swart AC (April 2018). "The in vitro metabolism of 11β-hydroxyprogesterone and 11- ... into 11β-hydroxyprogesterone. In addition, progesterone can be hydroxylated in the liver by other cytochrome P450 enzymes which ... 21-hydroxyprogesterone), respectively, and pregnanetriols are formed secondarily to 17α-hydroxylation. Even smaller amounts of ... 17 (5): 367-88. doi:10.1089/neu.2000.17.367. PMID 10833057. Pan DS, Liu WG, Yang XF, Cao F (October 2007). "Inhibitory effect ...
List of androgen esters § Testosterone esters Hydroxyprogesterone heptanoate benzilic acid hydrazone J. Elks (14 November 2014 ... Gleason CH, Parker JM (September 1959). "The duration of activity of the benziloyl hydrazones of testosterone-17-heptanoate, ... Testosterone enantate benzilic acid hydrazone (TEBH), or testosterone 17β-enantate 3-benzilic acid hydrazone, is a synthetic, ... Gleason CH (July 1964). "Testosterone 17-Heptanoate 3-Benziloylhydrazone". J. Med. Chem. 7 (4): 573. doi:10.1021/jm00334a042. ...
I. C21 steroids: progesterone, 16 alpha-hydroxyprogesterone, 17 alpha-hydroxyprogesterone, 20 alpha-dihydroprogesterone, delta ... I. C21 steroids: progesterone, 16ά-hydroxyprogesterone, 17ά -hydroxy-progesterone, 20ά-dihydroprogesterone, ∆5-pregnenolone, ∆5 ... 17 February 1984). "Delivery of a healthy infant following nonsurgical ovum transfer". JAMA. 251 (7): 889. doi:10.1001/jama. ... sulfate and 17-hydroxy ∆5-pregnenolone. J Clin Endocrinol Metab 48 (1) 33-38, 1979 Rodi IA, Sauer MV, Gorrill MJ, Bustillo M, ...
17-alpha-hydroxyprogesterone → (hydroxylation at C21) → 11-Deoxycortisol → (hydroxylation at C11) → Cortisol The adrenal cortex ...
17alpha-hydroxyprogesterone + NAD(P)H + H+ The 3 substrates of this enzyme are 17alpha,20alpha-dihydroxypregn-4-en-3-one, NAD+ ... Wiest WG (December 1968). "On the function of 20 alpha-hydroxypregn-4-en-3-one during parturition in the rat". Endocrinology. ... In enzymology, a 20-α-hydroxysteroid dehydrogenase (EC 1.1.1.149) is an enzyme that catalyzes the chemical reaction 17alpha, ... Shikita M, Inano H, Tamaoki B (1967). "Further studies on 20-alpha-hydroxysteroid dehydrogenase of rat testes". Biochemistry. 6 ...
On 17 June, he finished second in the Group 1 King's Stand Stakes behind Equiano. Four days later, he finished fourth in the ... press release 17 October 2006 Global Sprint Challenge "Superb win sets Takeover Target for Royal Ascot" Racing and Sports ... well clear of his closest competitor on 17 points. His return to racing in Australia in 2007 was delayed, first by an injury ... where he ran eighth in the Group 1 KrisFlyer International Sprint over 1,200 metres at Kranji Racecourse on 17 May 2009. From ...
MeSH D04.345.051.500 - crown ethers MeSH D04.345.103.222 - alpha-cyclodextrins MeSH D04.345.103.333 - beta-cyclodextrins MeSH ... 20-alpha-dihydroprogesterone MeSH D04.808.745.745.654.829.395 - hydroxyprogesterones MeSH D04.808.745.745.654.829.395.400 - 17- ... alpha-hydroxyprogesterone MeSH D04.808.745.745.654.829.614 - medroxyprogesterone MeSH D04.808.745.745.654.829.614.500 - ... 5-alpha-dihydroprogesterone MeSH D04.808.745.558.050 - alfaxalone alfadolone mixture MeSH D04.808.745.558.783 - ...
"6-methyl-17alpha-hydroxyprogesterone, the lower fatty acid 17-acylates and methods for producing the same", published 1968-04- ... Penning TM, Sharp RB, Krieger NR (December 1985). "Purification and properties of 3 alpha-hydroxysteroid dehydrogenase from rat ... and was thought to inhibit the signaling of proinflammatory cytokines such as interleukin 6 and tumor necrosis factor alpha, ... selective inhibition of 3 alpha-hydroxysteroid oxidoreductase activity". Journal of Steroid Biochemistry. 17 (2): 197-203. doi: ...
Johnson JW, Austin KL, Jones GS, Davis GH, King TM (October 1975). "Efficacy of 17alpha-hydroxyprogesterone caproate in the ... Hydroxyprogesterone caproate is the generic name of OHPC and its INN, USAN, BANM, and JAN, while hydroxyprogesterone hexanoate ... Estradiol valerate/hydroxyprogesterone caproate Estradiol benzoate/hydroxyprogesterone caproate Estradiol dipropionate/ ... It should also not be confused with hydroxyprogesterone acetate, hydroxyprogesterone heptanoate, or medroxyprogesterone acetate ...
... such as hydroxyprogesterone caproate and, to a far lesser extent, hydroxyprogesterone acetate and hydroxyprogesterone ... When "hydroxyprogesterone" is referenced from the standpoint of medical use, what is usually being referred to is actually, in ... Hydroxyprogesterone is the generic name of 17α-OHP and its INN and BAN. 11α-Hydroxyprogesterone 5α-Dihydroprogesterone 20- ... Among others, this class of drugs includes chlormadinone acetate, cyproterone acetate, hydroxyprogesterone caproate, ...
Thirteen patients with primary adenocarcinoma of the uterine corpus were treated for 21 days with 17alpha-hydroxy-progesterone- ... über den Stoffwechsel von 17alpha-Hydroxy-19-nor-progesteron-capronat beim Menschen in vivo und von 17alpha-Hydroxy-19-nor- ... It is approximately 20 to 25 times more potent than progesterone or hydroxyprogesterone caproate in animal bioassays when all ... The preparations used were Proluton Depot (17a-hydroxy-progesterone caproate) and in 3 patients SH 5132 (17a-hydroxy-19- ...
... alpha subunit MeSH D06.472.351.576.463 - luteinizing hormone MeSH D06.472.351.576.463.249 - glycoprotein hormones, alpha ... 20-alpha-dihydroprogesterone MeSH D06.472.334.851.687.750.099 - 5-alpha-dihydroprogesterone MeSH D06.472.334.851.687.750.478 - ... alpha-msh MeSH D06.472.699.631.525.690.583.075 - beta-msh MeSH D06.472.699.631.525.690.583.115 - gamma-msh MeSH D06.472.699.631 ... alpha-msh MeSH D06.472.734.525.690.583.075 - beta-msh MeSH D06.472.734.525.690.583.115 - gamma-msh MeSH D06.472.734.525.883 - ...
... (17α-BP) is a progestin which was first described in 1957 and was never marketed. It is about twice as ... 17α-BP is a parent compound of haloprogesterone (6α-fluoro-17α-bromoprogesterone) and 6α-methyl-17α-bromoprogesterone. 17α- ... Hydroxyprogesterone 17α-Methylprogesterone 19-Norprogesterone Engel CR, Jahnke H (November 1957). "Steroids and related ... X. 17 alpha-Bromoprogesterone, a new potent gestogen". Can J Biochem Physiol. 35 (11): 1047-55. doi:10.1139/o57-120. PMID ...
Progesterone → (hydroxylation at C17) → 17-alpha-hydroxyprogesterone → (hydroxylation at C21) → 11-Deoxycortisol → ( ...
In addition to progesterone, 20α- and 20β-hydroxyprogesterone (20α- and 20β-hydroxy-4-pregnene-3-one) also are found. These ... Storbeck KH, Swart P, Africander D, Conradie R, Louw R, Swart AC (2011). "16α-hydroxyprogesterone: origin, biosynthesis and ... include 16α-hydroxyprogesterone (16α-OHP),[8] 17α-hydroxyprogesterone (17α-OHP) (very weak),[9] 20α-dihydroprogesterone (20α- ... These progestogens, along with another steroid, 17α-hydroxypregnenolone, are the precursors of all other endogenous steroids, ...
The first product was 17alpha-acetoxyprogesterone4 (Figure 1) marketed under the trade name of Prodox.® Prodox was introduced ... 17a-hydroxyprogesterone caproate and 17a-hydroxyprogesterone acetate, introduced in 1953, and the most potent of all new ... Hydroxyprogesterone acetate is the generic name of the drug and its INN. OHPA is or was marketed under the brand name Prodox ... of hydroxyprogesterone a c e t a te, in bottles of 25 tablets. GREENBLATT RB (1959). "Hormonal control of functional uterine ...
A potent mineralocorticoid antagonist with reduced affinity for the 5 alpha-dihydrotestosterone receptor of human and rat ... 7α-Acetylthio-17α-hydroxyprogesterone, a related derivative of progesterone and also of 17α-hydroxyprogesterone, has been found ...
11 alpha-Hydroxyprogesterone (11 alpha OH-P) was an order of magnitude more potent a competitive inhibitor of the 11 beta HSD-2 ... Souness GW, Latif SA, Laurenzo JL, Morris DJ (1995). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta- ... Souness GW, Morris DJ (1996). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid ... 11α-Hydroxyprogesterone can therefore influence blood pressure regulation.12 Furthermore, 11α-hydroxyprogesterone exhibits an ...
MGA was the third synthetic derivative of progesterone to be developed for use as a medication, following hydroxyprogesterone ... hydroxyprogesterone caproate, medroxyprogesterone acetate, and nomegestrol acetate. MGA differs from medroxyprogesterone ... 17 (6 Suppl 9): 38-46. PMID 2148026. Doses [of megestrol acetate] of as high as 1,600 mg/d, given in divided doses three or ... 17 (4): 367-71. doi:10.1002/jso.2930170409. PMID 7265976. S2CID 72595843. Geller J, Albert J, Yen SS, Geller S, Loza D (March ...
Zander J, Forbes TR, Von Munstermann AM, Neher R (April 1958). "Delta 4-3-Ketopregnene-20 alpha-ol and delta 4-3-ketopregnene- ... ISBN 978-1-259-64116-9. In addition to progesterone, 20α- and 20β-hydroxyprogesterone (20α- and 20β-hydroxy-4-pregnene-3-one) ... 20β-Dihydroprogesterone (20β-DHP), also known as 20β-hydroxyprogesterone (20β-OHP), is an endogenous metabolite of progesterone ... 20α-Dihydroprogesterone 17α-Hydroxyprogesterone 16α-Hydroxyprogesterone 5α-Dihydroprogesterone 11-Deoxycorticosterone Bertram G ...
... labeled alpha- and beta- subunits) that are non-covalently associated: The alpha subunits of LH, FSH, TSH, and hCG are ... The gene for the alpha subunit is located on chromosome 6q12.21. The luteinizing hormone beta subunit gene is localized in the ... In contrast to the alpha gene activity, beta LH subunit gene activity is restricted to the pituitary gonadotropic cells. It is ... Each monomeric unit is a glycoprotein molecule; one alpha and one beta subunit make the full, functional protein. Its structure ...
Retrieved 2018-09-17. Štěrba, R. (1971). "On the Way to a More Physiological Hormonal Contraception". Current Problems in ... Shapiro EL, Weber L, Harris H, Miskowicz C, Neri R, Herzog HL (July 1972). "Synthesis and biological activity of 17-esters of 6 ... 17 (8): 898-900. doi:10.1021/jm00254a025. PMID 4845383. Topliss JG, Shapiro EL (June 1975). "Quantitative structure-activity ... ISBN 978-1-4615-8653-1. Cekan Z, Horesovský O (February 1971). "Elimination and metabolism of 6-chloro-17-alpha-hydroxy-16- ...
Souness GW, Latif SA, Laurenzo JL, Morris DJ (1995). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta- ... Souness GW, Morris DJ (1996). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid ... alpha)-methyl-androsta-1,4-diene-11 (alpha), 17 (beta)-diol-3-one) in humans". J. Int. Med. Res. 4 (2): 96-105. doi:10.1177/ ... Indeed, 11α- and 11β-hydroxyprogesterone (formebolone and roxibolone being 11α- and 11β-hydroxylated (respectively) similarly) ...
Souness GW, Latif SA, Laurenzo JL, Morris DJ (1995). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta- ... Souness GW, Morris DJ (1996). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid ... In accordance, 11α- and 11β-hydroxyprogesterone are known to be potent inhibitors of 11β-hydroxysteroid dehydrogenase (11β-HSD ... Roxibolone (INN) (developmental code name BR-906), also known as 11β,17β-dihydroxy-17α-methyl-3-oxoandrosta-1,4-diene-2- ...
The official start to its development started in December 1986 when Merck's president, Edward Scolnick, announced that they would start a comprehensive AIDS research program. They started a laboratory dedicated to AIDS research in West Point, Pennsylvania and placed Emilio Emini in charge of the laboratory.[11] A couple months later on January, 1987, a team of researchers consisting of Emilio Emini, Joel Huff, and Irving Sigal, kickstarted their studies by basing their project off of earlier research on the protease enzyme, renin.[5] They were the ones who started the process of research and development into protease inhibitors and its relation to the virus. Over a year later, in July 1988, Nancy Kohl, Emilio Emini, et al., published in the Proceedings of the National Academy of the Science about the idea of inhibiting the protease.[11] On February, 1989, Manuela Navia, Paula Fitzgerald, et al., published a paper that showed the three-dimensional structure of HIV's protease enzyme.[5] Other ...
InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H, 3,20H2, (H, 22,23)/ ... 17] Levothyroxine is taken on an empty stomach approximately half an hour to an hour before meals.[18] As such, thyroid ...
Progestogens (incl., chlormadinone acetate, cyproterone acetate, hydroxyprogesterone caproate, gestonorone caproate, ... norepinephrine due to lack of alpha-2 receptor negative feedback and decreased fat accumulation due to epinephrine/ ... increase beta adrenergic receptors while decreasing alpha adrenergic receptors- which results in increased levels of ... 17 (8): 951-63. doi:10.1517/14728222.2013.806491. PMID 23746222.. *^ Häggström, Mikael; Richfield, David (2014). "Diagram of ...
EIS results when the function of the estrogen receptor alpha (ERα) is impaired. The ERα protein (pictured) mediates most of the ... the estrogen receptor alpha (ERα) - that results in an inability of estrogen to mediate its biological effects in the body.[3] ... and at the age of 17 years, 8 months, her bone age was 13.5 years.[9] Her bone mass was lower than expected for her age, and ... 17α-hydroxyprogesterone, androstenedione, testosterone, and dihydrotestosterone (DHT) were elevated in the sisters, while ...
17][18] In addition to receiving FDA approval for traveler's diarrhea and (marketing approved for)[18] hepatic encephalopathy, ... 17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1 Y ... Alpha-Lipoic acid. *Ambrisentan. *AMI-193. *Amlodipine besylate ...
1S,2R,8S,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,8,15-trimethyltetracyclo[8.7.0.02,7.011,15]heptadeca-3,6- ... 17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1 Y ... 6α, 11β)-11,17,21-trihydroxy-6-methyl-pregna-1,4-diene-3,20-dione. ...
Hypomagnesemia[17]. Concern has been expressed regarding vitamin B12[18] and iron malabsorption,[19] but effects seem to be ... InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20) Y ... Archived from the original on November 17, 2016. Retrieved October 21, 2018.. ...
A potent mineralocorticoid antagonist with reduced affinity for the 5 alpha-dihydrotestosterone receptor of human and rat ... 11β-Hydroxyprogesterone. *16α,18-Dihydroxy-11-deoxycorticosterone. *17α-Hydroxyaldosterone ... 7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-7-methylsulfanylspiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene- ... 7α-TMS; SC-26519; 17α-Hydroxy-7α-(methylthio)-3-oxopregn-4-ene-21-carboxylic acid γ-lactone. ...
Bonow RO, Carabello BA, Kanu C, et al. (August 2006). "ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons". Circulation. 114 (5): e84-231. doi:10.1161/CIRCULATIONAHA.106.176857. PMID 16880336 ...
The alpha subunits of LH, FSH, TSH, and hCG are identical, and contain 92 amino acids in human but 96 amino acids in almost all ... In contrast to the alpha gene activity, beta LH subunit gene activity is restricted to the pituitary gonadotropic cells. It is ... Each monomeric unit is a glycoprotein molecule; one alpha and one beta subunit make the full, functional protein. ... The gene for the alpha subunit is located on chromosome 6q12.21. ... labeled alpha- and beta- subunits) that are non-covalently ...
Couse JF, Korach KS (December 2004). "Estrogen receptor-alpha mediates the detrimental effects of neonatal diethylstilbestrol ( ... Progestogens like hydroxyprogesterone caproate have been reported to reduce the nipple hyperpigmentation induced by high-dose ... doi:10.1016/s0022-5347(17)60564-0. PMID 4699685.. *^ a b c d e Scott WW, Menon M, Walsh PC (April 1980). "Hormonal Therapy of ... Prevention of the testosterone flare at the start of gonadotropin-releasing hormone agonist (GnRH agonist) therapy[15][16][17][ ...
"Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta". ... 16α-Hydroxyprogesterone. *17α-Hydroxyprogesterone. *20α-Dihydroprogesterone. *20β-Dihydroprogesterone ... 3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol ... Androstenediol, or 5-androstenediol (abbreviated as A5 or Δ5-diol), also known as androst-5-ene-3β,17β-diol, is an endogenous ...
Alpha lipoic acid. *Benfotiamine. *Botulinum toxin A. *Bupropion. *Cannabinoids (e.g., cannabis, dronabinol, nabilone) ... InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18) Y ... 17] abnormal heart rhythms, blurry or double vision.[2] Also, rare case reports of an auditory side effect have been made, ...
Chu YH, Li QA, Zhao ZF, Zhou YP, Cao DC (1985). "[Antiprogestational action of 5 alpha-dihydronorethisterone]". Zhongguo Yao Li ... Progestogens (e.g., chlormadinone acetate, cyproterone acetate, gestonorone caproate, hydroxyprogesterone caproate, ... Progestogens (incl., chlormadinone acetate, cyproterone acetate, hydroxyprogesterone caproate, gestonorone caproate, ... "Vasodilating effect of norethisterone and its 5 alpha metabolites: a novel nongenomic action". Eur. J. Pharmacol. 475 (1-3): ...
16α-Hydroxyprogesterone. *17α-Hydroxyprogesterone. *20α-Dihydroprogesterone. *20β-Dihydroprogesterone ... 1-[(3S,8S,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17 ... InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-, ... Pregnenolone is lipophilic and readily crosses the blood-brain barrier.[17] This is in contrast to pregnenolone sulfate, which ...
"Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta". Biochemical ... 16α-Hydroxyprogesterone. *17α-Hydroxyprogesterone. *20α-Dihydroprogesterone. *20β-Dihydroprogesterone ... 8R,9S,13S,14S,16R,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16,17-triol ... InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3/t13-, ...
InChI=1S/C21H20Cl2O3/c1-21(2)17(12-18(22)23)19(21)20(24)25-13-14-7-6-10-16(11-14)26-15-8-4-3-5-9-15/h3-12,17,19H,13H2,1-2H3 ... Archived from the original on 17 April 2014. Retrieved 19 April 2014.. ...
"Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein". Invest New Drugs. 14 (2): 147-51. doi:10.1007 ... 17 Sep 2006). Last modified Jul 2005. *^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad Clarke SJ, Rivory LP ( ... 65 (17): 2513-31. doi:10.2165/00003495-200565170-00007. PMID 16296875.. *^ Shelley, M; Harrison, C; Coles, B; Staffurth, J; ... 19 (17): 2419-26. Bibcode:2005RCMS...19.2419G. doi:10.1002/rcm.2072. PMID 16059877.. ...
17,25,27-29,32H,1H2,2-3H3,(H2,23,31)/t10-,14-,15+,17+,22+/m1/s1 Y ... Alpha-Lipoic acid. *Ambrisentan. *AMI-193. *Amlodipine besylate ...
InChI=1S/C16H15Cl3O2/c1-20-13-7-3-11(4-8-13)15(16(17,18)19)12-5-9-14(21-2)10-6-12/h3-10,15H,1-2H3 Y ...
The mechanism of activating the promoter for SHBG in the liver involves hepatocyte nuclear factor 4 alpha (HNF4A) binding to a ... Hydroxyprogesterone. 0.8. 9.9. 5.4. 2.50. 0.31. 41.3. 55.9. 1.8. 2.44. 0.73. 42.1. 54.7 ... As an example anti-psoriatic drugs that inhibit TNF-alpha cause an increase in SHBG. The common downstream mechanism for all of ... and cytokines like TNF-alpha and Interleukin reduce SHBG, whereas insulin does not. ...
16α-Hydroxyprogesterone. *17α-Hydroxyprogesterone. *20α-Dihydroprogesterone. *20β-Dihydroprogesterone ... 1-[(3R,5R,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a] ... InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15-,16+ ... InChI=1/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15-,16+, ...
ഈ താൾ അവസാനം തിരുത്തപ്പെട്ടത്: 20:17, 21 ഡിസംബർ 2019.. *വിവരങ്ങൾ ക്രിയേറ്റീവ് കോമൺസ് ആട്രിബ്യൂഷൻ-ഷെയർഎലൈക്ക് അനുമതിപത്ര പ്രകാരം ...
17][18] Loratadine is almost totally (97-99%) bound to plasma proteins. Its metabolite desloratadine, which is largely ...
Lee JY, Cho KS (May 2018). "Effects of 5-alpha reductase inhibitors: new insights on benefits and harms". Curr Opin Urol. 28 (3 ... Progestogens (incl., chlormadinone acetate, cyproterone acetate, hydroxyprogesterone caproate, gestonorone caproate, ... Trost L, Saitz TR, Hellstrom WJ (2013). "Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review". Sex Med Rev. 1 ... "FDA Alert: 5-alpha reductase inhibitors (5-ARIs): Label Change - Increased Risk of Prostate Cancer". Drugs.com. Retrieved 2014- ...
Blackburn CM, Childs DS (March 1959). "Use of 2 alpha-methyl androstan-17 beta-ol, 3-one (2-methyl dihydrotestosterone) in the ... Progestogens (incl., chlormadinone acetate, cyproterone acetate, hydroxyprogesterone caproate, gestonorone caproate, ... 5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3- ... 17α-Alkylated derivatives. *Marketed *Androisoxazole (a 2,3-isoxazole A ring-fused derivative of 17α-methyl-DHT) ...
It inhibits production of interleukin (IL)-12, interferon (IFN)-gamma, IFN-alpha, and tumor-necrosis-factor (TNF)-alpha by ... 11β-Hydroxyprogesterone. *16α,18-Dihydroxy-11-deoxycorticosterone. *17α-Hydroxyaldosterone ... Cortisol is also metabolized into 5-alpha tetrahydrocortisol (5-alpha THF) and 5-beta tetrahydrocortisol (5-beta THF), ... reactions for which 5-alpha reductase and 5-beta reductase are the rate-limiting factors, respectively. 5-Beta reductase is ...
Trost L, Saitz TR, Hellstrom WJ (2013). "Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review". Sex Med Rev. 1 ... Progestogens (incl., chlormadinone acetate, cyproterone acetate, hydroxyprogesterone caproate, gestonorone caproate, ... "FDA Alert: 5-alpha reductase inhibitors (5-ARIs): Label Change - Increased Risk of Prostate Cancer". Drugs.com. Retrieved 2014- ... Wang LG, Mencher SK, McCarron JP, Ferrari AC (2004). "The biological basis for the use of an anti-androgen and a 5-alpha- ...
"DHEA metabolites activate estrogen receptors alpha and beta". Steroids. 78 (1): 15-25. doi:10.1016/j.steroids.2012.10.002. PMC ... "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta". ... Thus, 17,20-lyase is required for the synthesis of androstenedione, whether immediately or one step removed. Androstenedione is ... Androstenedione, or 4-androstenedione (abbreviated as A4 or Δ4-dione), also known as androst-4-ene-3,17-dione, is an endogenous ...
InChI=1S/C15H10O4/c16-10-6-11(17)15-12(18)8-13(19-14(15)7-10)9-4-2-1-3-5-9/h1-8,16-17H Y ...
CHEBI:17252 - 17α-hydroxyprogesterone. Main. ChEBI Ontology. Automatic Xrefs. Reactions. Pathways. Models. ... 17α-hydroxyprogesterone (CHEBI:17252) is a 17α-hydroxy-C21-steroid (CHEBI:138141) 17α-hydroxyprogesterone (CHEBI:17252) is a ... 17α-hydroxyprogesterone (CHEBI:17252) has role progestin (CHEBI:59826) 17α-hydroxyprogesterone (CHEBI:17252) is a 17α-hydroxy ... 17(16). 7-. 10-. 20(18,21). 3/h12,16-. 18,24H,4-. 11H2,1-. 3H3/t16-. ,17+,18+,19+,20+,21+/m1/s1. ...
17α-Hydroxyprogesterone Coated Tube RIA Kit The kit is ready to use and includes the following components: Antibody Coated ... 17α-Hydroxyprogesterone Double Antibody RIA Kit The kit is ready to use and includes the following components: Antiserum, 7 ... 17α-Hydroxyprogesterone Antiserum for 3H Assay (Sheep) Antibody is purified from sheep and is sufficient for 1,000 tubes. ...
... alpha-Hydroxyprogesterone Caproate. Robert Egerman,1 Risa Ramsey,2 Niki Istwan,3 Debbie Rhea,3 and Gary Stanziano3 ... alpha-hydroxyprogesterone caproate (17OHPC) for preterm delivery prevention. Materials and Methods. Retrospectively identified ... alpha-hydroxyprogesterone caproate (17OHPC) administration to women with a singleton gestation having a history of a preterm ... α-hydroxyprogesterone caproate," The New England Journal of Medicine, vol. 348, no. 24, pp. 2379-2385, 2003. View at Google ...
This study was undertaken to assess the impact of 17 alpha hydroxyprogesterone caproate treatment on future medical costs for ... Data on the costs of preterm birth were combined with published data on the effectiveness of 17 alpha hydroxyprogesterone ... These estimates were compared with an estimate of the cost of a typical 17 alpha hydroxyprogesterone caproate treatment regimen ... Treatment is estimated to reduce initial neonatal hospitalization costs by $3800 per woman treated with 17 alpha ...
6 alpha Methyl 17alpha hydroxyprogesterone Acetate. A synthetic progestin that is derived from 17-Hydroxyprogesterone. It is a ...
11-hydroxyprogesterone. Castor Oil. Progestins. Hormones. Hormones, Hormone Substitutes, and Hormone Antagonists. Physiological ... Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate. The safety and scientific validity ... The objective of our study is to compare the effectiveness of weekly intramuscular injections of 17-alpha Hydroxyprogesterone ... Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate. ...
Meaning of 17-alpha-hydroxyprogesterone. What does 17-alpha-hydroxyprogesterone mean? Information and translations of 17-alpha- ... hydroxyprogesterone in the most comprehensive dictionary definitions resource on the web. ... Definition of 17-alpha-hydroxyprogesterone in the Definitions.net dictionary. ... Discuss these 17-alpha-hydroxyprogesterone definitions with the community:. Word of the Day. Would you like us to send you a ...
Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 ... Impact of single nucleotide polymorphisms on P450 oxidoreductase and peroxisome proliferator-activated receptor alpha on ... Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 ... Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 ...
... alpha»-Hydroxyprogesterone, TMS derivative. *Formula: C24H38O3Si ...
strong,Sheep anti Human 17-alpha-Hydroxyprogesterone-3-Cmo antibody,/strong, recognizes 17-Alpha-Hydroxyprogesterone-3-CMO, a ... Sheep anti Human 17-alpha-Hydroxyprogesterone-3-Cmo antibody recognizes 17-Alpha-Hydroxyprogesterone-3-CMO, a progestogen which ... Request a different product with the 17-alpha-Hydroxyprogesterone-3-Cmo specificity ...
Buy 17-α-Hydroxyprogesterone 17-acetate - CAS Number 302-23-8 from LGC Standards. Please login or register to view prices, ... Hydroxyprogesterone Acetate ;. Megestrol Acetate Imp. K (Pharmeuropa) ;Medroxyprogesterone Acetate Imp. H (EP) ; Megestrol ... InChI=1S/C23H32O4/c1-14(24)23(27-15(2)25)12-9-20-18-6-5-16-13-17(26)7-10-21(16,3)19(18)8-11-22(20,23)4/h13,18-20H,5-12H2,1-4H3/ ... K (EP) ; 3,20-Dioxopregn-4-en-17-yl Acetate ; Chlormadinone acetate EP impurity G ;. Read more.. ...
Active Comparator: hydroxyprogesterone caproate 250 mg Pregnant subject will receive 250mg of hydroxyprogesterone caproate ... Experimental: hydroxyprogesterone caproate 500 mg Pregnant subject will receive 500mg of hydroxyprogesterone caproate ... Hydroxyprogesterone Caproate. 11-hydroxyprogesterone. Premature Birth. Obstetric Labor, Premature. Obstetric Labor ... Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm Birth (PRO). The safety and ...
Note that 3,17-diacetoxy-6-methylpregna-4,6-dien-20-one (1b), a structural analog of compound 1a, is certified in Russia under ... It is very close to megestrol acetate (6-dehydro-6-methyl-17α-acetoxyprogesterone) in structure, except that there is a ... A closely related medication is cymegesolate (also known as megestrol 3β-cypionate 17α-acetate), which, in contrast, has not ... Nikitina GV, Savchenko ON, Stepanov MG (1987). "[Hormonal properties of new 17 alpha-hydroxyprogesterone derivatives]". ...
Johnson JW, Austin KL, Jones GS, Davis GH, King TM (October 1975). "Efficacy of 17alpha-hydroxyprogesterone caproate in the ... Hydroxyprogesterone caproate is the generic name of OHPC and its INN, USAN, BANM, and JAN, while hydroxyprogesterone hexanoate ... Estradiol valerate/hydroxyprogesterone caproate Estradiol benzoate/hydroxyprogesterone caproate Estradiol dipropionate/ ... It should also not be confused with hydroxyprogesterone acetate, hydroxyprogesterone heptanoate, or medroxyprogesterone acetate ...
The postnatal 17-OHP level may be considered as a measure for severity of intrauterine stress and might be used as an ... METHODS: We analyzed 17-OHP and TSH levels during neonatal screenings in the first hours of life of 90 premature infants born ... 17-alpha-Hydroxyprogesterone / blood*. Biological Markers / blood. Chorioamnionitis / blood*. Female. Fetal Growth Retardation ... 17-OHP was even higher when intrauterine growth restriction was present (99.8 nmol/L). Antenatal steroids and mode of delivery ...
17-Alpha-Hydroxyprogesterone (17-OHP). View cart "Complete Blood Count" has been added to your cart. ... 17 OHP along with Cortisol and Androstenedione constitutes the best screening test for Congenital adrenal hyperplasia caused by ...
Hydroxyprogesterone Caproate reference guide for safe and effective use from the American Society of Health-System Pharmacists ... The effect of esterases on 17alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 2008; 198:229.e1-5. ... Identification of enzymes involved in the metabolism of 17alpha-hydroxyprogesterone caproate: an effective agent for prevention ... Hydroxyprogesterone Caproate Pharmacokinetics. Pharmacokinetics of the 250-mg dose of hydroxyprogesterone caproate not ...
Converts progesterone to its inactive form, 20-alpha-dihydroxyprogesterone (20-alpha-OHP). In the liver and intestine, may have ... phenylalanine and 17alpha-hydroxyprogesterone in blood spots. J Inherit Metab Dis. 2007 Aug;30(4):609. Epub 2007 Jun 14. [ ... 17alpha,20alpha-Dihydroxypregn-4-en-3-one + NAD(P)(+) → 17-Hydroxyprogesterone + NAD(P)H. details. ... dihydrotestosterone to 5-alpha-androstane-3 beta,17 beta-diol, dehydroepiandrosterone to androstenedione and 5-alpha-androstan- ...
Synthesis of 19-nor-17 alpha-hydroxy-progesterone-caprona. By admin October 27, 2019 Uncategorized 0 Comments ... HomeSynthesis of 19-nor-17 alpha-hydroxy-progesterone-caprona. ...
Human steroidogenic cytochrome P450 17A1 mutant A105L with substrate 17alpha-hydroxyprogesterone. *DOI: 10.2210/pdb4NKY/pdb ... Steroid 17-alpha-hydroxylase/17,20 lyase. A, B, C, D. 494. Homo sapiens. Mutation(s): 1 Gene Names: CYP17, CYP17A1, S17AH. EC: ... 9beta)-17-hydroxypregn-4-ene-3,20-dione. C21 H30 O3. DBPWSSGDRRHUNT-CEGNMAFCSA-N. Ligand Interaction. ... Although 17α-hydroxyprogesterone is only observed farther from the catalytic iron, 17α-hydroxypregnenolone is also observed ...
PATIENTS AND METHODS We analysed neonatal dried blood spots from 753 subjects with transiently elevated levels of 17-OHP. The ... RESULT Among the 701 successfully sequenced samples from subjects with transiently elevated 17-OHP, 670 (95%) had no point ... 17-OHP). These children require regular follow-up until normalization of their 17-OHP levels. We investigated the possibility ... of the genotyped subjects that had transiently elevated 17-OHP, the performance of the tests was suboptimal when performed ...
... alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, ... alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, glucose-6-phosphate dehydrogenase, hemoglobin A, ... 17. The sensor of claim 1. , wherein a thickness of the resistance domain is from about 0.05 microns to about 5 microns. ... Jun 17, 2003. Therasense, Inc.. Blood analyte monitoring through subcutaneous measurement. US6689265 *. Mar 23, 2001. Feb 10, ...
... rotating the sensor seventeen times by 120( for at least six layers of 360( coverage) and curing at 50(C under vacuum for 60 ... alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, ... alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, glucose-6-phosphate dehydrogenase, hemoglobin A, ... 17. The system of claim 1. , wherein the sensor is configured to extend from the housing by a distance, wherein the distance ...
Equipped with the best GMP factory of best quality 17 Alpha hydroxyprogesterone Factory for cosmetic, health care and human ... it is able to supply you with top quality 17 Alpha hydroxyprogesterone Factory USP/EP 99%, as well as the reactive intermediate ... Hydroxyprogesterone caproate. Synonyms: OHPC; Hydroxyprogesterone hexanoate; 17α-Hydroxyprogesterone caproate; 17α-OHPC; 17- ... Contact Now Hydroxyprogesterone Caproate,17α-Hydroxyprogesterone caproateProduct Name: ...
What is hydroxyprogesterone caproate? Meaning of hydroxyprogesterone caproate medical term. What does hydroxyprogesterone ... Looking for online definition of hydroxyprogesterone caproate in the Medical Dictionary? hydroxyprogesterone caproate ... hydroxyprogesterone caproate. Also found in: Wikipedia. hydroxyprogesterone caproate. (hye-drox-ee-pro-jess-te-rone kap-roe-ate ... Tenders are invited for Inj Hydroxyprogesterone Caproate 250 Mg 1 Ml. Inj Hydroxyprogesterone Caproate 250 Mg 1 Ml ...
Pregnancy and neonatal outcomes of women receiving compounded 17-alpha hydroxyprogesterone at San Juan City hospital ... More than 75% of the patients prolonged their pregnancy with the use of 17alpha-hydroxyprogesterone. Continuation of the study ... To describe the pregnancy and neonatal outcomes of women receiving 17alpha-hydroxyprogesterone to prevent subsequent preterm ... Pregnancy and neonatal outcomes of women receiving compounded 17-alpha hydroxyprogesterone at San Juan City hospital. ...
Transforming Growth Factor Alpha (TGF-Alpha), Hepatocyte Growth Factor, Tumor Necrosis Factor-Alpha (TNF-Alpha), Placental ... Transforming Growth Factor Alpha, Hepatocyte Growth Factor, Tumor Necrosis Factor-Alpha, Angiogenin, Interleukin-8, Hypoxia ... Transforming Growth Factor Alpha, Hepatocyte Growth Factor, Tumor Necrosis Factor-Alpha, Angiogenin, Interleukin-8, Hypoxia ... alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, ...
... alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, ... alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, analyte-6-phosphate dehydrogenase, hemoglobinopathies ... 17. The method of claim 15. , further comprising a step of filtering at least one glucose-related sensor data point when ... 17 alpha-hydroxyprogesterone; hypoxanthine phosphoribosyl transferase; immunoreactive trypsin; lactate; lead; lipoproteins ((a ...
17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized ... Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003 Jun 12. 348(24):2379-85. ... CL, cervical length; PTB, preterm birth; 17P, 17-alpha-hydroxy-progesterone caproate; TVT, transvaginal ultrasound. Reprinted ...
11-hydroxyprogesterone. Estrogen Antagonists. Hormone Antagonists. Hormones, Hormone Substitutes, and Hormone Antagonists. ... 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. Am J Obstet ... Treatment with 17 alpha-hydroxyprogesterone caproate via weekly injections of 250 mg of 17p until 37 weeks gestation or ... Drug: 17 alpha-hydroxyprogesterone caproate Coded study medication is sterile solution containing 250 mg/mL of 17 alpha- ...
  • A 17α-hydroxy steroid that is the 17α-hydroxy derivative of progesterone. (ebi.ac.uk)
  • The objective of our study is to compare the effectiveness of weekly intramuscular injections of 17-alpha Hydroxyprogesterone Caproate, a natural metabolite of progesterone, in preventing delivery at less than 37 weeks of gestation in a population of 290 patients with twin gestations between 16 and 36 weeks of gestation compared to a placebo. (clinicaltrials.gov)
  • A metabolite of PROGESTERONE with a hydroxyl group at the 17-alpha position. (definitions.net)
  • Acetomepregenol, also known as megestrol 3β,17α-diacetate, as well as 3β-dihydro-6-dehydro-6-methyl-17α-hydroxyprogesterone diacetate or as 3β,17α-diacetoxy-6-methylpregna-4,6-dien-20-one, is a synthetic pregnane steroid and a derivative of progesterone and 17α-hydroxyprogesterone. (wikipedia.org)
  • Whether chronic stress, as reflected by intrauterine growth retardation, influences the level of 17-OH progesterone (17-OHP), was not previously examined. (biomedsearch.com)
  • Second, both hydroxylase substrates pregnenolone and progesterone hydrogen bond to Asn(202) in orientations consistent with production of 17α-hydroxy major metabolites, but functional and structural evidence for an A105L mutation suggests that a minor conformation may yield the minor 16α-hydroxyprogesterone metabolite. (rcsb.org)
  • It is derived from progesterone via 17-hydroxylase, a P450c17 enzyme, or from 17-hydroxypregnenolone via 3β-hydroxysteroid dehydrogenase/Δ5-4 isomerase. (hmdb.ca)
  • Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. (uniprot.org)
  • My doctor advised me I needed to start progesterone shots at 17 weeks. (medhelp.org)
  • Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery. (nih.gov)
  • Two recent double blind randomized placebo controlled trials reported lower preterm birth rate with the use of either intramuscular 17 alpha-hydroxyprogesterone caproate (IM 17OHP-C) or intravaginal micronized progesterone suppositories in women at risk for preterm delivery. (dovepress.com)
  • A microsomal hemeprotein that catalyses two independent reactions at the same active site - the 17alpha-hydroxylation of pregnenolone and progesterone, which is part of glucocorticoid hormones biosynthesis, and the conversion of the 17alpha-hydroxylated products via a 17,20-lyase reaction to form androstenedione and dehydroepiandrosterone, leading to sex hormone biosynthesis (EC 1.14.14.32 , 17alpha-hydroxyprogesterone deacetylase). (kegg.jp)
  • There is no evidence that 17-α-hydroxyprogesterone caproate can reduce the rate of preterm delivery in women with a short cervix, and therefore, the compound of choice is natural progesterone (not the synthetic progestin). (degruyter.com)
  • 7α-Acetylthio-17α-hydroxyprogesterone, a related derivative of progesterone and also of 17α-hydroxyprogesterone, has been found to possess potent antimineralocorticoid activity similarly. (wikipedia.org)
  • Background: 17-alpha Hydroxyprogesterone caproate for prevention of recurrent preterm birth is recommended for use in the United States. (elsevier.com)
  • Objective: We sought to assess the clinical effectiveness of 17-alpha hydroxyprogesterone caproate to prevent recurrent preterm birth ≤35 weeks compared to similar births in our obstetric population prior to the implementation of 17-alpha hydroxyprogesterone caproate. (elsevier.com)
  • Third, the mean (±SD) interval in weeks of recurrent preterm birth before 17-alpha hydroxyprogesterone caproate use was 0.4 ± 5.3 weeks and the interval of recurrent preterm birth after 17-alpha hydroxyprogesterone caproate treatment was 0.1 ± 4.7 weeks (P = .63). (elsevier.com)
  • Conclusion: 17-alpha Hydroxyprogesterone caproate was ineffective for prevention of recurrent preterm birth and was associated with an increased rate of gestational diabetes. (elsevier.com)
  • The appropriate use of 17-P can prevent recurrent preterm birth. (astho.org)
  • CONCLUSION: Women with singleton gestations receiving weekly 17α-hydroxyprogesterone caproate for recurrent preterm birth prevention had a significantly higher incidence of abnormal glucose test results and GDM compared with those in unexposed control groups, a finding that did not hold among women who had been randomly allocated to 17α-hydroxyprogesterone caproate. (elsevier.com)
  • 1 Other studies have shown that 17-OHP in 24-hour urine correlated well with serum 17-OHP and suggested that the urine measurement of 17-OHP may be a reliable alternative to serum 17-OHP measurement for monitoring of CAH therapy. (labcorp.com)
  • The diagnosis of NCAH relies on serum 17-hydroxyprogesterone (17-OHP) concentrations. (nih.gov)
  • Hypersensitivity to hydroxyprogesterone or castor oil;History of or known thrombosis/thromboembolic disorder;History of or known/suspected breast cancer or other hormone-sensitive cancer;Unexplained abnormal vaginal bleeding unrelated to pregnancy;Cholestatic jaundice of pregnancy;Benign/malignant liver tumors or active liver disease;Uncontrolled hypertension. (thefreedictionary.com)
  • It is very close to megestrol acetate (6-dehydro-6-methyl-17α-acetoxyprogesterone) in structure, except that there is a hydroxyl group with an acetate ester attached at the C3 position instead of a ketone. (wikipedia.org)
  • A closely related medication is cymegesolate (also known as megestrol 3β-cypionate 17α-acetate), which, in contrast, has not been marketed. (wikipedia.org)
  • 17 OHP along with Cortisol and Androstenedione constitutes the best screening test for Congenital adrenal hyperplasia caused by either 11 or 21 hydroxylase deficiency. (apollodiagnostics.in)
  • The androgens (testosterone, free testosterone, DHEA-S, androstenedione)and 17 alpha hydroxyprogesterone will be measured at baseline and again will be measured at the end of the trial by day 90. (knowcancer.com)
  • By performing a 4-year retrospective data review, we were able to test 121 dried blood spots from newborns with positive CAH screening for 17-OHP, androstenedione and cortisol levels by LC-MS/MS. We prospectively evaluated the clinical utility of steroid profiling after the implementation of steroid profiling as a second-tier test in our routine clinical practice. (degruyter.com)
  • 3. Shibata Y. Determination of urinary 17 alpha-hydroxyprogesterone excretion using ELISA--evaluation of normal subjects and patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. (labcorp.com)
  • Measurements of levels of 17-hydroxyprogesterone are useful in the evaluation of patients with suspected congenital adrenal hyperplasia as the typical enzymes that are defective, namely 21-hydroxylase and 11β-hydroxylase, lead to a build-up of 17OHP. (hmdb.ca)
  • In contrast, the rare patient with 17α-hydroxylase deficiency will have very low or undetectable levels of 17OHP. (hmdb.ca)
  • 17 hydroxyprogesterone for the prevention of preterm delivery. (nih.gov)
  • We examined maternal factors influencing the development of gestational diabetes (GDM) in obese women receiving 17- alpha -hydroxyprogesterone caproate (17OHPC) for preterm delivery prevention. (hindawi.com)
  • A side effect of weekly 17-alpha hydroxyprogesterone caproate injections was an increase in gestational diabetes. (elsevier.com)
  • Specifically, the rate of gestational diabetes was 13.4% in 17-alpha hydroxyprogesterone caproate-treated women compared to 8% in case-matched controls (P = .001). (elsevier.com)
  • OBJECTIVE: To evaluate whether 17α-hydroxyprogesterone caproate use in preventing preterm birth increases the risk of gestational diabetes mellitus (GDM). (elsevier.com)
  • Pregnant subject will receive 250mg of hydroxyprogesterone caproate Intramuscular injection weekly from 16 0/7-36 6/7 weeks or delivery which ever occurs first. (clinicaltrials.gov)
  • Pregnant subjects randomized to this study arm will receive a weekly Intramuscular injection of 250mg hydroxyprogesterone caproate injection weekly from 16 0/7 to 36 6/7 weeks or delivery which ever is first. (clinicaltrials.gov)
  • Pregnant subject will receive 500mg of hydroxyprogesterone caproate Intramuscular injection weekly from 16 0/7-36 6/7 weeks or delivery which ever occurs first. (clinicaltrials.gov)
  • A synthetic progestin that is derived from 17-Hydroxyprogesterone . (online-medical-dictionary.org)
  • Hydroxyprogesterone caproate (OHPC), sold under the brand names Proluton and Makena among others, is a progestin medication which is used to prevent preterm birth in pregnant women with a history of the condition and to treat gynecological disorders. (wikipedia.org)
  • 17-Hydroxyprogesterone is a natural progestin and in pregnancy increases in the third trimester primarily due to fetal adrenal production. (hmdb.ca)
  • Sheep anti Human 17-alpha-Hydroxyprogesterone-3-Cmo antibody recognizes 17-Alpha-Hydroxyprogesterone-3-CMO, a progestogen which may reduce the risk of pre-term delivery in pregnant women. (bio-rad-antibodies.com)
  • 17-Hydroxyprogesterone in premature infants as a marker of intrauterine stress. (biomedsearch.com)
  • METHODS: We analyzed 17-OHP and TSH levels during neonatal screenings in the first hours of life of 90 premature infants born between 25 and 33 weeks of gestation in infants with AI (n=37) or with PE (n=53). (biomedsearch.com)
  • Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. (mdedge.com)
  • The study plans to determine the relationship between plasma concentrations of 17-OHPC ( hydroxyprogesterone caproate) and the rate of preterm birth. (clinicaltrials.gov)
  • The study will determine the association between plasma concentrations of 17-OHPC (hydroxyprogesterone caproate) and the rate of preterm birth and will evaluate the impact of several potential covariates on plasma concentrations of 17-OHPC and its efficacy. (clinicaltrials.gov)
  • These women are insulin resistant and have compensatory hyperinsulinemia that stimulates ovarian cytochrome P450c17 alpha activity that in turn stimulates ovarian androgen concentrations. (knowcancer.com)
  • The report provides comprehensive information on the Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. (bioportfolio.com)
  • Additionally, the report provides an overview of key players involved in Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30 targeted therapeutics development and features dormant and discontinued projects. (bioportfolio.com)
  • Treatment is estimated to reduce initial neonatal hospitalization costs by $3800 per woman treated with 17 alpha hydroxyprogesterone caproate. (ovid.com)
  • To describe the pregnancy and neonatal outcomes of women receiving 17alpha-hydroxyprogesterone to prevent subsequent preterm birth in our institution. (geoscience.net)
  • 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial. (medscape.com)
  • Genetic analysis of the CYP21A2 gene in neonatal dried blood spots from children with transiently elevated 17-hydroxyprogesterone. (semanticscholar.org)
  • BACKGROUND Neonatal screening for congenital adrenal hyperplasia (CAH) identifies a certain proportion of newborns with transient moderate elevation of 17-hydroxyprogesterone (17-OHP). (semanticscholar.org)
  • An asymptomatic 32-year-old woman with a prior preterm delivery, presently pregnant with a singleton at 17 weeks of gestation, underwent transvaginal ultrasonography and was found to have a cervical length of 22 mm and dense intra-amniotic sludge. (mdedge.com)
  • Treatment with 17 alpha-hydroxyprogesterone caproate via weekly injections of 250 mg of 17p until 37 weeks gestation or delivery vs. weekly injections of placebo oil until 37 weeks gestation or delivery. (clinicaltrials.gov)
  • All subjects will have trough blood samples collected immediately prior to their second injection of the 17-OHPC, at 26-30 weeks (but only after a minimum of 7 injections have been administered) , 6-9 weeks later and at the time of delivery. (clinicaltrials.gov)
  • AUC 1 done after 4 weekly 17-OHPC injections completed, between 20 6/7 to 24 6/7 weeks gestation. (clinicaltrials.gov)
  • The American Congress of Obstetricians and Gynecologists (ACOG) and the Society for Maternal Fetal Medicine Publications Committee suggest offering 17- alpha -hydroxyprogesterone caproate (17OHPC) administration to women with a singleton gestation having a history of a preterm birth [ 1 ]. (hindawi.com)
  • Wong and coworkers showed that measurement of 17-OHP in 24-hour urine produced results that may be useful for monitoring glucocorticoid and mineralocorticoid therapy in patients with congenital adrenal hyperplasia (CAH). (labcorp.com)
  • Urinary 17 alpha-hydroxyprogesterone in diagnosis and management of congenital adrenal hyperplasia. (labcorp.com)
  • hydroxyprogesterone in dried blood samples on filter paper and its application to mass screening for congenital adrenal hyperplasia. (nii.ac.jp)
  • Mutations in this gene are associated with isolated steroid-17 alpha-hydroxylase deficiency, 17-alpha-hydroxylase/17,20-lyase deficiency, pseudohermaphroditism, and adrenal hyperplasia. (thermofisher.com)
  • More than 75% of the patients prolonged their pregnancy with the use of 17alpha-hydroxyprogesterone. (geoscience.net)
  • Third, was duration of pregnancy modified by 17-alpha hydroxyprogesterone caproate treatment compared to a prior preterm birth? (elsevier.com)
  • The North Carolina Division of Public Health is working with the NC Division of Medical Assistance and Community Care of North Carolina to include 17-P as a part of the Pregnancy Medical Home (PMH) program. (astho.org)
  • Eke, A , Sheffield, J & Graham, EM 2019, ' 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis ', Obstetrics and gynecology , vol. 133, no. 3, pp. 468-475. (elsevier.com)
  • Fourth, differential positioning of 17α-hydroxypregnenolone offers a mechanism whereby allosteric binding of cytochrome b5 might selectively enhance the lyase reaction. (rcsb.org)
  • Since lean PCOS women do not have the option of weight loss, it is important to know if composition and meal timing distribution may influence glucose metabolism and hyperandrogenism and cytochrome P450c17 alpha activity. (knowcancer.com)
  • It has both 17alpha-hydroxylase and 17,20-lyase activities and is a key enzyme in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens. (thermofisher.com)
  • METHODS OF STUDY SELECTION: Studies comparing 17α-hydroxyprogesterone caproate with unexposed control groups in women with singleton gestation and a history of a prior spontaneous preterm birth were included. (elsevier.com)
  • A basal 17-OHP concentration ≥2 ng/ml (6 nmol/l) should be used for screening if more appropriate in-house cut-off values are not available. (nih.gov)
  • In conjunction with spectroscopic evidence, this suggests that only 17α-hydroxypregnenolone approaches and interacts with the proximal oxygen of the catalytic iron-peroxy intermediate, yielding efficient production of dehydroepiandrosterone as the key intermediate in human testosterone and estrogen synthesis. (rcsb.org)
  • The first abstract suggests that HCG at least partially blocks the conversion of 17 alpha-hydroxyprogesterone (17 OHP), a testosterone precursor, to testosterone. (anabolicminds.com)
  • Fluorescence enzyme immunoassay of 17.ALPHA. (nii.ac.jp)
  • Subjects are randomized to a weekly single injection of either 250 or 500mg 17-OHPC ( hydroxyprogesterone caproate). (clinicaltrials.gov)
  • Stetson B, Hibbard JU, Wilkins I, Leftwich H. Outcomes with cerclage alone compared with cerclage plus 17 α-hydroxyprogesterone caproate. (mdedge.com)
  • Treating expectant mothers with a prior spontaneous preterm birth with 17 alpha hydroxyprogesterone caproate generates future medical cost savings that substantially exceed the cost of treatment. (ovid.com)
  • The potential benefit of identifying a therapeutic concentration range and of optimizing the dosage of 17-OHPC are substantial. (clinicaltrials.gov)
  • Second, was recurrence of preterm birth related to 17-alpha hydroxyprogesterone caproate plasma concentration? (elsevier.com)
  • Definitive diagnosis requires a 17-OHP concentration ≥10 ng/ml (30 nmol/l), either basally or after cosyntropin-stimulation. (nih.gov)
  • 17-OHP was even higher when intrauterine growth restriction was present (99.8 nmol/L). Antenatal steroids and mode of delivery did not significantly affect 17-OHP levels. (biomedsearch.com)
  • First, 17-alpha hydroxyprogesterone caproate did not significantly reduce the rates of recurrence regardless of prior preterm birth number or sequence. (elsevier.com)
  • 2. Lim YJ, Yong AB, Warne GL, Montalto J. Urinary 17 alpha-hydroxyprogesterone in management of 21-hydroxylase deficiency. (labcorp.com)
  • Third, substrate specificity of the subsequent 17,20-lyase reaction may be explained by variation in substrate height above the heme. (rcsb.org)
  • Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. (uniprot.org)
  • Are we missing a good definition for 17-alpha-hydroxyprogesterone ? (definitions.net)
  • 17-Hydroxyprogesterone (17-OHP) in urine is greatly elevated in patients with polycystic ovarian disease and in patients with idiopathic hirsutism. (labcorp.com)
  • The most commonly used substance was 17-alpha hydroxyprogesterone caproate. (medhelp.org)